[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 182
1. Obed A, Tsui TY, Schnitzbauer AA, Obed M, Schlitt HJ, Becker H, Lorf T: Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg; 2008 Mar;393(2):141-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?
  • BACKGROUND: Liver transplantation is considered as one of therapeutic approaches to hepatocellular carcinoma (HCC).
  • Patients were treated either with primary tumour resection, transarterial chemoembolisation (TACE) or liver transplantation (LTx) by an interdisciplinary team.
  • RESULTS: The overall 1-year and 5-year survivals of patients in LTx group were 95 and 57%, respectively, which were significantly higher than those in primary tumour resection group (65 and 33%, P < 0.01) and those in TACE group (44 and 4%, P < 0.01).
  • In parallel, 1-year and 5-year tumour-free survivals of patients in LTx group (75 and 62%) were significantly higher than those in primary tumour resection group (50 and 11%, P < 0.01).
  • There were no significant differences in 1- and 5-year survivals of patients with early tumour stage received LTx or primary tumour resection, whereas patients in advanced tumour stage based on pathological findings of explanted liver significantly benefited from LTx as compared to primary resection.
  • CONCLUSIONS: LTx can be a curative approach for patients with advanced HCC without extrahepatic metastasis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Liver Transpl. 2006 Aug;12(8):1260-7 [16826556.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):877-83 [11679986.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):474-86 [11685740.001]
  • [Cites] Ann Surg. 2002 May;235(5):722-30; discussion 730-1 [11981219.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9 [14530722.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:9-16 [9210883.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1572-7 [9620329.001]
  • [Cites] Transpl Int. 1998;11 Suppl 1:S189-92 [9664976.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):953-9 [9875642.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):324-31 [10458250.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S113-9 [16286887.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):212-7 [16613896.001]
  • [Cites] Transplant Proc. 2006 May;38(4):1111-3 [16757280.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1224-9 [11093728.001]
  • (PMID = 18043937.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3085731
  •  go-up   go-down


2. Sun HW, Chen LH, Wei CJ, Zheng XK, Li QS, Guan J: [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jun;29(6):1133-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
  • OBJECTIVE: To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE).
  • Child-Pugh grade A of liver cirrhosis was present in 64 cases and grade B in 20 cases.
  • CONCLUSION: 3-DCRT combined with TACE has definite therapeutic effect on advanced massive PLC, and Child-Pugh grade is an independent prognostic factor in such cases.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Hepatocellular / therapy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Mitomycin / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726341.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / hydroxycamptothecinum; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Wu MC: [Progress in diagnosis and treatment of primary liver cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug;30(4):363-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress in diagnosis and treatment of primary liver cancer].
  • The early diagnosis, surgical treatment, and comprehensive treatment of primary liver cancer (PLC) have advanced greatly in recent years.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Early Diagnosis. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795602.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Nashimoto A, Yabusaki H, Nakagawa S, Takii Y, Tsuchiya Y, Otsuo T: Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer. Anticancer Res; 2009 Nov;29(11):4689-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer.
  • PATIENTS AND METHODS: In total, 120 consecutive patients with highly advanced gastric cancer were treated with S-1 (80 mg/m(2) for 21 consecutive days) and cisplatin (50 mg/m(2) on day 8).
  • The median survival time was 41.9 months among 93 patients whose primary lesion was resected.
  • Liver metastasis, R2 resection, poor performance status and lack of response were identified as independent risk factors by a multivariate analysis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Combinations. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oxonic Acid / administration & dosage. Oxonic Acid / adverse effects. Retrospective Studies. Survival Rate. Tegafur / administration & dosage. Tegafur / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032421.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Lin HT, Liu GJ, Wu D, Lou JY: Metastasis of primary gallbladder carcinoma in lymph node and liver. World J Gastroenterol; 2005 Feb 7;11(5):748-51
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of primary gallbladder carcinoma in lymph node and liver.
  • AIM: To evaluate the patterns with metastasis of gallbladder carcinoma in lymph nodes and liver.
  • The patterns with metastasis of primary gallbladder carcinoma in lymph nodes and liver were examined histopathologically and classified as TNM staging of the American Joint Committee on Cancer.
  • RESULTS: Of the 45 patients, 29 (64.4%) had a lymph node positive disease and 20 (44.4%) had a direct invasion of the liver.
  • The frequency of involvement of lymph nodes was strongly influenced by the depth of the primary tumor (P = 0.0001).
  • CONCLUSION: Complete resection of the regional lymph nodes is important in advanced primary gallbladder carcinoma (PGC).
  • The initial sites of liver spread are located mostly in segments IV and V.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Liver Neoplasms / secondary. Lymphatic Metastasis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholecystectomy. Hepatectomy. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655837.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4250754
  •  go-up   go-down


6. van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ: Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol; 2008 Jul;15(7):1891-8
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
  • PURPOSE: The liver is one of the most common sites for metastatic solid tumors.
  • If the liver is the only site of metastatic disease, regional treatment options can offer the benefit of high local exposure with limited systemic toxicity, especially for patients without (further) systemic treatment options.
  • We report the results of our experience with isolated hepatic perfusion (IHP) in patients with isolated liver metastases from a variety of primary tumors.
  • PATIENTS AND METHODS: Nineteen patients with isolated unresectable liver metastases from a variety of tumors (13 uveal melanomas, 2 neuroendocrine carcinomas, 2 gastrointestinal stromal tumors, 1 hepatocellular carcinoma, and 1 high-grade sarcoma) were treated with a 60-min IHP using 200 mg melphalan.
  • RESULTS: One melanoma patient was not perfused due to insufficient isolation of the liver.
  • Fifty percent of other primary tumors showed at least partial remission, including one complete remission in a high-grade sarcoma patient.
  • CONCLUSION: IHP with melphalan shows activity in patients with liver metastases from a variety of primary tumors, but other or additional drugs may improve therapeutic outcome.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melphalan / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1479-89 [9552055.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):36-8 [9499254.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Surgery. 2004 Dec;136(6):1176-82 [15657573.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Int Ophthalmol Clin. 2006 Winter;46(1):151-66 [16365561.001]
  • [Cites] Arch Surg. 2006 Feb;141(2):181-90 [16490897.001]
  • [Cites] Semin Nucl Med. 2006 Apr;36(2):147-56 [16517236.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):578-83 [16469752.001]
  • [Cites] Dig Dis Sci. 2006 Jun;51(6):1033-8 [16865563.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Eur J Surg Oncol. 2007 Sep;33(7):874-81 [17400422.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1539-46 [10789721.001]
  • [Cites] Digestion. 2000;62 Suppl 1:92-7 [10940694.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3062-70 [10955785.001]
  • [Cites] Surg Oncol. 2000 Aug;9(2):67-70 [11094325.001]
  • [Cites] J Surg Res. 2001 Jan;95(1):8-12 [11120628.001]
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] J Gastroenterol. 2000 Dec;35(12):907-11 [11573726.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1052-6 [12016482.001]
  • [Cites] Am Surg. 2002 Sep;68(9):827-31 [12356160.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):1005-10 [14500219.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1391-7 [14598420.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6343-9 [14695133.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):200-7 [15036196.001]
  • [Cites] Melanoma Res. 2004 Feb;14(1):67-72 [15091197.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):830-2 [15143927.001]
  • [Cites] Cancer Immunol Immunother. 2004 Sep;53(9):840-1 [15127238.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):334-6 [6190546.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):663-6 [2427948.001]
  • [Cites] Int J Rad Appl Instrum B. 1987;14(2):113-8 [3597112.001]
  • [Cites] Surv Ophthalmol. 1988 Jan-Feb;32(4):239-51 [3279559.001]
  • [Cites] Dig Dis Sci. 1989 Mar;34(3 Suppl):14S-27S [2920654.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):891-6 [2124136.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Acta Oncol. 1991;30(4):503-7 [1854508.001]
  • [Cites] Anticancer Drugs. 1994 Oct;5(5):503-19 [7858282.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):76-82 [7740814.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1665-70 [8635073.001]
  • [Cites] Gastroenterol Clin North Am. 1995 Dec;24(4):969-90 [8749907.001]
  • [Cites] Jpn J Clin Oncol. 1996 Oct;26(5):341-50 [8895675.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):568-72 [9856657.001]
  • (PMID = 18470571.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2467497
  •  go-up   go-down


7. Zhu Lz, Yang Rj: [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage]. Beijing Da Xue Xue Bao; 2008 Apr;40(2):129-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage].
  • CONCLUSION: Primary hepatic carcinoma with AVS increases difficulty of interventional therapyìbut as long as we take active and proper treating measureìwe could acquire satisfactory curative effect without serious syndrome.
  • DSA can demonstrate the type, the site and the degree of AVS completely and directly, thus having important value in treating primary hepatic carcinoma and improving prognosis.
  • [MeSH-major] Angiography, Digital Subtraction. Arteriovenous Fistula / radiography. Arteriovenous Fistula / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / radiography. Female. Hepatic Artery / abnormalities. Humans. Male. Middle Aged. Portal Vein / abnormalities. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458684.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Guan CN, Cai LZ, Yue LQ, Zhang Y: [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy]. Zhongguo Zhong Yao Za Zhi; 2006 Mar;31(6):510-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy].
  • OBJECTIVE: To study the effects of Yanshu injection on the combined treatment in the advanced primary liver cancer.
  • METHOD: Eighty-five cases of advanced primary liver cancer were treated with Yanshu injection combining with chemotherapy or only chemotherapy.
  • CONCLUSION: Yanshu injection combination with chemotherapy can raise the curative effect, one year survival rate and cellular immune function, reduce pain genesic rate and toxicity of chemotherapy, and improve the quality of life of the patients with advanced primary liver cancer, which is worthy to be recommended for clinical application.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Liver Neoplasms / drug therapy. Phytotherapy. Sophora
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Therapy, Combination. Female. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Plants, Medicinal / chemistry. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722388.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


9. Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH: The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum; 2009 Jan;52(1):23-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases.
  • PURPOSE: This study was designed to investigate the outcome of "the liver-first" approach in patients with locally advanced rectal cancer and synchronous liver metastases.
  • METHODS: Patients with locally advanced rectal cancer and synchronous liver metastases were primarily treated for their liver metastases.
  • One patient had liver resection without neoadjuvant chemotherapy followed by chemoradiotherapy.
  • Eighteen patients underwent partial liver resection and subsequent chemoradiotherapy for the rectal cancer.
  • One patient underwent in one session a partial liver resection and a low anterior resection.
  • CONCLUSIONS: This is the first sizable report on the "liver-first approach" demonstrating that it may be considered the preferred treatment schedule for patients with locally advanced rectal cancer and synchronous liver metastases.
  • It allows most patients to undergo curative resections of both metastatic and primary disease and can avoid useless rectal surgery in patients with incurable metastatic disease.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Laparotomy. Male. Middle Aged. Neoadjuvant Therapy. Treatment Failure

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273952.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg; 2006 Jul;93(7):872-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary.
  • BACKGROUND: In many patients with advanced synchronous liver metastases from colorectal tumours, the metastases progress during treatment of the primary, precluding curative treatment.
  • The authors have investigated a management strategy that involves high-impact chemotherapy first, resection of liver metastases second and finally removal of the primary tumour in patients with adverse prognostic factors.
  • METHODS: Twenty consecutive patients with non-obstructive colonic (nine patients) or rectal (11 patients) cancer and advanced synchronous liver metastases were treated according to this strategy.
  • Sixteen of the 20 patients had complete removal of liver metastases and colorectal tumours (resectability rate 80 per cent).
  • It allows initial control and downstaging of liver metastases, and delivery of preoperative radiotherapy for rectal cancer without the fear that liver metastases will meanwhile progress beyond the possibility of cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Prospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 British Journal of Surgery Society Ltd.
  • [CommentIn] Br J Surg. 2006 Dec;93(12):1564; author reply 1564 [17115402.001]
  • [CommentIn] Br J Surg. 2007 Feb;94(2):250 [17256815.001]
  • [CommentIn] Br J Surg. 2006 Nov;93(11):1434; author reply 1434 [17058298.001]
  • (PMID = 16671066.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Wang B, Tian HQ, Liang GW: [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Mar;29(3):257-60
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer].
  • OBJECTIVE: To observe and compare the quality of life (QOL) and survival time in patients with advanced primary hepatic cancer (PHC) after they have been treated by the combination of ganji recipe and interventional therapy with Fructus Bruceae Oil Emulsion (FBE) or by the trans-hepatic arterial chemical embolization (TACE) adopting Seldinger's technique.
  • METHODS: Seventy-seven patients with advanced PHC were randomly assigned to two groups, 37 patients in the control group treated with TACE alone, and 40 in the treatment group with the combined therapy.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548447.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Plant Oils
  •  go-up   go-down


12. Fléchon A, Rivoire M, Berger N: [Surgery of residual masses after chemotherapy in patients with testicular cancer]. Rev Prat; 2007 Feb 28;57(4):389-98
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of residual masses after chemotherapy in patients with testicular cancer].
  • [Transliterated title] Chirurgie des masses résiduelles après chimiothérapie du cancer du testicule.
  • Advanced non seminomatous germ cell tumours are rare diseases affecting young men.
  • Advanced disease is curable in 80% of the cases.
  • The primary site of metastases is the retroperitoneal lymph nodes.
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Controlled Clinical Trials as Topic. Follow-Up Studies. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Positron-Emission Tomography. Postoperative Complications. Prognosis. Prospective Studies. Radiotherapy Dosage. Retroperitoneal Space. Seminoma / drug therapy. Seminoma / radionuclide imaging. Seminoma / surgery. Teratoma / surgery. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455741.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 52
  •  go-up   go-down


13. Verslype C, Libbrecht L: The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Pract Res Clin Gastroenterol; 2007;21(6):983-96
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults.
  • The finding of a focal solid liver lesion represents a challenge for the clinician in terms of the most optimal diagnostic and therapeutic algorithm.
  • Tumours may arise from hepatocytes (hepatocellular adenoma, dysplastic nodules and carcinoma), bile ducts (cholangiocarcinoma) or mesenchymal tissue (hemangioma, epithelioid haemangioendothelioma), or are metastases from primary tumours outside the liver.
  • However, small hypervascular lesions in a cirrhotic liver may be difficult to characterise.
  • The therapy of a focal liver lesion is determined by its natural history and the functional status of the surrounding liver parenchyma.
  • Selected patients with primary liver cancer are candidates for liver transplantation, while patients with advanced malignant tumours have a poor outcome.
  • [MeSH-major] Bile Duct Neoplasms. Liver Cirrhosis / complications. Liver Neoplasms. Precancerous Conditions
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / etiology. Adenoma, Liver Cell / therapy. Adult. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangiocarcinoma / therapy. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / etiology. Focal Nodular Hyperplasia / therapy. Hemangioma / diagnosis. Hemangioma / etiology. Hemangioma / therapy. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070699.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


14. Tsuyuki S, Kawaguchisakita N, Tsubota Y, Ukikusa M, Kohno Y: [More effective positioning of capecitabine for advanced and metastatic breast cancer]. Gan To Kagaku Ryoho; 2010 Apr;37(4):649-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [More effective positioning of capecitabine for advanced and metastatic breast cancer].
  • We investigated 30 patients with advanced and metastatic breast cancer who underwent capecitabine therapy in our department from July, 2004 to April, 2009.
  • Of these patients, 17 had bone, 15 lymph node, 13 lung, 7 liver, and 4 skin metastasis.
  • The soft tissue lesions(primary tumor and metastasis of skin and lymph nodes)showed a significantly better response to capecitabine treatment than other metastases such as lung, liver and bone.
  • There was a significant difference in the response rate between soft tissue metastasis (lymph nodes, skin and primary tumor)and other types of metastasis (lung, liver, and bone).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Female. Humans. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Staging. Receptor, ErbB-2 / metabolism. Survival Rate


15. Zhao M, Wang JP, Wu PH, Zhang FJ, Huang ZL, Li W, Zhang L, Pan CC, Li CX, Jiang Y: [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Nov 9;90(41):2916-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the clinical efficacy and survival rate of transarterial chemoembolization (TACE) alone or plus radiofrequency ablation (RFA) in patients with intermediate or advanced stage primary hepatocellular carcinoma (HCC).
  • For the advanced stage HCC, the median survival time was 12 months, one-year survival rate 35%, three-year survival rate 7.1% and five-year survival rate 0 in the TACE alone group versus 28 months, 62.1%, 24.1% and 6.9% in the TACE plus RFA group (P = 0.00).
  • There was significantly statistic difference between both groups in intermediate and advanced staging HCC.
  • CONCLUSION: The regimen of TACE plus RFA has the advantages of tumor control, liver function protection and survival extending in the treatment of HCC than TACE alone in intermediate or advanced stage HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Embolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211397.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M: S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology; 2007 Dec;54(80):2315-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas.
  • BACKGROUND/AIMS: 5-FU plus Cisplatin combination therapy had been employed against primary liver carcinomas for years.
  • S-1 is a fourth-generation oral fluoropyrimidine and attracts considerable interest for the activity against gastric cancer.
  • We herein examined the effect and adverse effects of S-1 plus Cisplatin combination therapy for primary liver carcinomas.
  • They all had far-advanced diseases in and/or out of the liver at the time of the therapy initiation.
  • CONCLUSIONS: S-1 plus Cisplatin combination therapy is a potential therapy for advanced primary liver carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Oxonic Acid / administration & dosage. Prognosis. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265655.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Nukaya H, Kajino S, Tokuda H, Tanaka Y, Hasegawa I, Kato A, Joh T: [Bi-weekly docetaxel and doxifluridine combination therapy in pretreated patients with unresectable and/or advanced gastric cancer]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1713-7
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bi-weekly docetaxel and doxifluridine combination therapy in pretreated patients with unresectable and/or advanced gastric cancer].
  • We report an investigation of the therapeutic efficacy and safety of combination chemotherapy with docetaxel (DOC) and doxifluridine (5'-DFUR) administered as second-line or third-line chemotherapy in 23 cases of unresectable and/or advanced gastric cancer.
  • 8% for primary tumors (2/17), 33.3% for lymph nodes (3/9) , and 26.9% for liver metastasis (1/7).
  • Our data suggest that the combination of docetaxel and 5'-DFUR has a promising therapeutic index in patients with unresectable advanced gastric cancer as second-line or third-line chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20841933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 039LU44I5M / Floxuridine; 15H5577CQD / docetaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


18. Fanfani F, Fagotti A, Gallotta V, Ercoli A, Pacelli F, Costantini B, Vizzielli G, Margariti PA, Garganese G, Scambia G: Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol; 2010 Mar;116(3):497-501
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery.
  • OBJECTIVE: Upper abdominal spread of primary and recurrent ovarian cancer is often considered to be a major obstacle to achieve optimal residual disease at the end of surgery.
  • In this study, we investigate the role of diaphragmatic debulking in the natural history of advanced and recurrent epithelial ovarian cancer patients, and the morbidity of this procedure according to clinico-surgical characteristics.
  • METHODS: Data from 234 consecutive patients with primary and recurrent advanced ovarian cancer, operated at Catholic University of Rome and Campobasso from January 1, 2005 and December 31, 2008, were retrospectively reviewed.
  • Diaphragmatic debulking was performed in 50 out of 120 patients at primary surgery (41.7%), in 16 out of 74 at interval debulking surgery (21.6%) and in 21 out of 40 secondary cytoreductions (52.5%).
  • Presence of a post-operative pleural effusion was correlated liver mobilization (52.3% vs. 16%; p<0.0027) and large diaphragmatic disease (>5 cm) removal (54.1% vs. 23.5%; p<0.034).
  • CONCLUSIONS: Diaphragmatic surgery represents a crucial step in the debulking of advanced and recurrent ovarian cancer patients.
  • Considering the natural history of advanced epithelial ovarian cancer and the rate of patients needing diaphragmatic debulking during primary cytoreduction, interval debulking surgery and secondary cytoreduction, this procedure should be present in the surgical repertoire of a gynecologic oncologist.
  • [MeSH-minor] Abdomen / pathology. Abdomen / surgery. Adult. Aged. Disease-Free Survival. Female. Gynecologic Surgical Procedures / adverse effects. Gynecologic Surgical Procedures / methods. Humans. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20004958.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mizutani S, Oyama T, Hatanaka N, Uchikoshi F, Yoshidome K, Tori M, Ueshima S, Okuma K, Hiraoka K, Yamagami Y, Takahashi H, Sueyoshi K, Taira M, Nakahara M, Nakao K: [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers]. Gan To Kagaku Ryoho; 2006 Mar;33(3):327-31
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
  • We conducted combined therapy of weekly paclitaxel and doxifluridine (5'-DFUR) for 23 cases of advanced and recurrent gastric carcinomas to investigate their efficacy and safety.
  • One of the CR cases was an unresectable case involving a primary tumor, liver metastasis, and abdominal lymph node metastasis, while the other was a recurrent case involving abdominal lymph node metastasis.
  • Combination therapy of weekly paclitaxel and 5'-DFUR can be an effective and safe therapy for advanced and recurrent gastric carcinomas.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Floxuridine / administration & dosage. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


20. Kawamura Y, Ikeda K, Kumada H: [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin]. Gan To Kagaku Ryoho; 2010 Mar;37(3):402-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin].
  • In this report, we retrospectively studied 152 consecutive patients with advanced HCC resistant to TACE using epirubicin, and all cases were treated with platinum derivatives using transcatheter arterial chemotherapy.
  • A number of molecular-based chemotherapeutic agents are expected to become available in the future, and the primary therapy of advanced stage HCC may change with the introduction of these drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Platinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Chemoembolization, Therapeutic. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332675.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Platinum Compounds; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


21. Nukaya H, Hirashima N, Tanaka Y, Endo M, Matsunaga S, Hasegawa I, Kato A, Sakakibara K, Sakamoto T, Kondo H: [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1421-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
  • We report an investigation of the therapeutic efficacy and safety of TS-1 single-agent therapy administered as first-line therapy in 23 cases of unresectable advanced gastric cancer treated at our institution.
  • By site, the response rate was 43.5% for primary tumors (10/23), 33.3% for lymph nodes (3/9), and 16.7% for liver metastasis (1/6).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Drug-Induced Liver Injury. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227741.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 12
  •  go-up   go-down


22. Idasiak A, Masłyk B, Blamek S, Suwiński R: [Risk of distant metastases after postoperative radiation therapy for locally advanced laryngeal cancer]. Otolaryngol Pol; 2008;62(2):149-57
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk of distant metastases after postoperative radiation therapy for locally advanced laryngeal cancer].
  • PURPOSE: To evaluate the prognostic factors for the risk of distant metastases after postoperative radiotherapy for laryngeal cancer.
  • MATERIAL AND METHODS: Medical records of 267 patients cancer treated between 1997 and 2003 were analyzed.
  • All pts had locally advanced squamous cell laryngeal cancer treated with surgery and postoperative radiotherapy.
  • The lungs and bones were the most common sites of metastases (58% and 33% respectively), whereas metastases to liver (6%) and brain (3%) were rare.
  • Localization of cancer (glottic vs. supraglottic) and number of positive lymph nodes at pathological staging significantly and independently affected MFS.
  • CONCLUSIONS: Number of positive lymph nodes in pathological specimen and site of primary cancer (glottic vs. supraglottic) significantly and independently predict a risk of distant metastases in combined modality treatment for laryngeal cancer.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Incidence. Laryngectomy / statistics & numerical data. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Poland / epidemiology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637438.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


23. Lam PT, Leung MW, Tse CY: Identifying prognostic factors for survival in advanced cancer patients: a prospective study. Hong Kong Med J; 2007 Dec;13(6):453-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identifying prognostic factors for survival in advanced cancer patients: a prospective study.
  • OBJECTIVE: To identify potential prognostic factors affecting the survival in patients with advanced cancer in a local palliative care unit.
  • PATIENTS: All advanced cancer in-patients and out-patients who were enrolled into the palliative care service of the United Christian Hospital between January and December 2002 were recruited.
  • The most frequent primary malignancy was lung (n=58, 34%), followed by liver (n= 24, 14%) and lower gastro-intestinal tract (n=24, 14%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057434.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Serum Albumin
  •  go-up   go-down


24. Stone P, Kelly L, Head R, White S: Development and validation of a prognostic scale for use in patients with advanced cancer. Palliat Med; 2008 Sep;22(6):711-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and validation of a prognostic scale for use in patients with advanced cancer.
  • The aim of this study was to develop a new prognostic indicator to help predict survival in advanced cancer patients more accurately.
  • Four variables were found to be associated with worse survival: primary lung cancer, secondary liver cancer, raised C-Reactive protein and poor performance status (ECOG 4).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Life Expectancy. London. Male. Middle Aged. Prognosis. Proportional Hazards Models. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715969.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


25. Ji SH, Park YS, Lee J, Lim DH, Park BB, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K: Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer. Jpn J Clin Oncol; 2005 Apr;35(4):214-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
  • BACKGROUND: We evaluated the efficacy and tolerability of a modified biweekly irinotecan, 5-fluorouracil and leucovorin regimen (modified Douillard regimen) as the first-line therapy in patients with advanced colorectal cancer.
  • METHODS: A total of 80 patients (41 male, 39 female) with recurrent or metastatic colorectal cancer were enrolled between April 2001 and December 2003.
  • The primary end-point was response rate, and the secondary end-points were time to progression and toxicity profile.
  • CONCLUSION: We conclude that the modified Douillard regimen may be a practical and more tolerable treatment option in patients with advanced colorectal cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Leukopenia / chemically induced. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15845571.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Zhu J, Wang Y, Hou M, Li HY, Zhang J: Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. Oncology; 2007;73(5-6):324-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
  • BACKGROUND: About 80% of patients with gastrointestinal stromal tumor (GIST) experience tumor recurrence or metastasis after a prior radical resection, and the most common metastatic site is the liver.
  • Imatinib mesylate has been proven to be effective in advanced GIST.
  • The current pilot study was designed to observe imatinib mesylate treatment for GIST patients who experienced sole liver metastasis after primary tumor resection.
  • The primary end points were grade 3-4 hematological or non-hematological toxicity and progression-free survival; the secondary end points were response rate and overall survival.
  • CONCLUSIONS: Imatinib mesylate treatment proved safe and effective for GIST patients who had liver metastasis alone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pilot Projects. Postoperative Complications / drug therapy. Postoperative Complications / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18497504.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


27. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Koyama M, Tanaka H, Matsueda K, Muto T: Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis; 2009 Jun;11(5):464-9
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer.
  • OBJECTIVE: Preoperative use of emission tomography with(18)F-fluorodeoxyglucose (FDG-PET) in patients with primary colorectal cancer remains controversial.
  • This study evaluated the additional value of FDG-PET in comparison with routine multidetector row computed tomography (MDCT) in patients with primary colorectal cancer.
  • METHOD: Retrospective analysis was performed in 65 patients with colorectal cancer who underwent whole-body FDG-PET.
  • Results of FDG-PET were compared with routine preoperative evaluation by MDCT regarding detection of primary tumour, lymph node involvement and distant metastases.
  • Liver metastases were present in 22 patients.
  • CONCLUSION: Preoperative FDG-PET is not superior to MDCT for detection of primary tumour, lymph node involvement or liver metastases, but may have potential clinical value in patients with advanced colorectal cancer by detecting extrahepatic distant metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637927.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol; 2005 Sep 20;23(27):6657-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
  • METHODS: The primary objective of this study was to determine the proportion of patients with advanced HCC who were progression-free at 6 months.
  • Forty-seven percent of patients had received prior chemotherapy for advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Neoplasm Invasiveness / pathology. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170173.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N0-1 CM17104
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


29. Iguchi T, Arai Y, Inaba Y, Yamaura H, Sato Y, Miyazaki M, Shimamoto H: Hepatic arterial infusion chemotherapy through a port-catheter system as preoperative initial therapy in patients with advanced liver dysfunction due to synchronous and unresectable liver metastases from colorectal cancer. Cardiovasc Intervent Radiol; 2008 Jan-Feb;31(1):86-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy through a port-catheter system as preoperative initial therapy in patients with advanced liver dysfunction due to synchronous and unresectable liver metastases from colorectal cancer.
  • PURPOSE: We retrospectively evaluated the safety and efficacy of preoperative initial hepatic arterial infusion chemotherapy (HAIC) through a port-catheter system in patients with liver dysfunction due to synchronous and unresectable liver metastases.
  • The aim of HAIC was to improve patients' clinical condition for later surgical removal of primary colorectal cancer.
  • METHODS: Port-catheter systems were placed radiologically in 21 patients (mean age 58.6 +/- 8.1 years) with liver dysfunction due to synchronous liver metastases from colorectal cancer.
  • Surgical removal of the primary lesion was planned after HAIC improved the liver function.
  • HAIC was performed a mean of 4.5 +/- 3.0 times and the liver function improved in all patients.
  • Curative (n = 18) or palliative (n = 1) surgical removal of the primary lesion was performed.
  • CONCLUSION: Initial HAIC administration is a safe and efficacious method for improving liver function prior to operative resection of primary colorectal cancer in patients with liver dysfunction due to synchronous and unresectable liver metastases.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / pathology. Fluorouracil / therapeutic use. Hepatic Artery. Liver Diseases / drug therapy. Liver Neoplasms / drug therapy. Preoperative Care / methods
  • [MeSH-minor] Adult. Aged. Catheters, Indwelling / adverse effects. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Liver / drug effects. Liver / surgery. Male. Middle Aged. Radiology, Interventional / methods. Retrospective Studies. Severity of Illness Index. Survival Analysis. Treatment Outcome


30. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, Verkh L, Huang X, Kern KA, Miller K: An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol; 2010 Jul;21(7):1436-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
  • BACKGROUND: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC).
  • We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC.
  • Study endpoints included safety (primary endpoint), pharmacokinetics, and antitumor activity.
  • CONCLUSIONS: These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC.


31. Hu JL, Huang JJ, Fu XH: [Survival status and prognostic factors of liver metastases from colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):286-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival status and prognostic factors of liver metastases from colorectal cancer].
  • OBJECTIVE: To analyze the survival status and prognostic factors of patients with liver metastases from colorectal cancer.
  • METHODS: The survival rate and prognostic factors of 112 patients with liver metastases from colorectal cancer, who had complete follow-up data, were retrospectively assessed by Kaplan-Meier analysis and multivariate regression analysis.
  • Univariate analysis demonstrated that gender, age, primary tumor site, chemotherapy and pathological types had no significant correlation with the overall survival.
  • But the treatment of primary tumor, time of liver metastasis, gross type of tumor, resection of liver metastases and clinical stage status were all independently related with the prognosis of patients.
  • Multivariate regression analysis showed that resection of liver metastases, gross type of tumor and clinical stage were key factors affecting the prognosis of patients with liver metastases from colorectal cancer.
  • CONCLUSION: Patients with advanced stage, infiltrative gross type of colorectal cancer should be followed-up closely so that liver metastases from the cancer can be diagnosed and treated early.
  • Resection of both the primary tumor and liver metastasis may improve survival of the patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510081.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W: Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg; 2005 Jun;241(6):839-45; discussion 845-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of advanced-stage carcinoid tumors: lessons learned.
  • OBJECTIVE: To evaluate clinical outcomes in a large group of advanced-stage carcinoid patients (stage IV) following multimodal surgical therapy.
  • SUMMARY BACKGROUND DATA: Patients with advanced-stage carcinoid have traditionally experienced poor 5-year survival (18%-30%).
  • Two- and four-year survival for patients with no or unilateral liver metastases (n = 23) was 89%, while 2- and 4-year survival for patients with bilateral liver disease (n = 59) was 68% and 52% (P = 0.072), respectively.
  • CONCLUSION: We think that all patients with advanced-stage carcinoid should be evaluated for possible multimodal surgical therapy.
  • Primary tumors should be resected, even in the presence of distant metastases to prevent future intestinal obstruction.
  • The "wait and see" method of management of this slow-growing cancer no longer has merit.
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Antineoplastic Agents, Hormonal / administration & dosage. Chemoembolization, Therapeutic. Female. Humans. Intestinal Obstruction / etiology. Liver Neoplasms / secondary. Male. Malignant Carcinoid Syndrome / etiology. Middle Aged. Neoplasm Staging. Octreotide / administration & dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2002 Aug;68(8):667-71; discussion 671-2 [12206599.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):742-56 [15358337.001]
  • [Cites] Surgery. 1990 Dec;108(6):1091-6 [1701060.001]
  • [Cites] Am J Surg. 1995 May;169(5):523-8 [7747834.001]
  • [Cites] World J Surg. 1996 Sep;20(7):908-14; discussion 914-5 [8678970.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):790-8; discussion 798-800 [12796575.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • [Cites] Surgery. 2001 Oct;130(4):677-82; discussion 682-5 [11602899.001]
  • (PMID = 15912033.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC1357164
  •  go-up   go-down


33. Evans MD, Escofet X, Karandikar SS, Stamatakis JD: Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol; 2009;7:28
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer.
  • BACKGROUND: The management of patients with surgically incurable bowel cancer at presentation is controversial.
  • It has been believed that the most effective palliation is achieved by resection of the primary cancer in order to pre-empt future complications.
  • This study reviews and compares the outcomes of patients with incurable bowel cancer managed by resection and non-resection strategies over a 7-year period in a single District General Hospital.
  • PATIENTS AND METHODS: All patients with surgically incurable bowel cancer at presentation were identified from the prospectively collected local ACPGBI database.
  • Survival, using Kaplan-Meier method and log-rank test, was compared between patients managed by resection of the primary, non-resectional intervention (surgery, stent & oncological treatments) and those managed with supportive care only.
  • The primary endpoint of the study was survival on an intention to treat basis, compared using Kaplan-Meier and log-rank tests.
  • RESULTS: Of 646 consecutive newly diagnosed bowel cancer patients over a 7 year period 154 cases (24%) were deemed surgically incurable at presentation.
  • Only one patient (2%) managed by non-resectional intervention required later surgery to treat primary tumour related complications.
  • CONCLUSION: In an unselected bowel cancer population surgical resection of the primary tumour in patients presenting with incurable disease does not improve survival and is associated with a high risk of post-operative mortality.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):636-52 [3042304.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):343-52 [7513600.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] Dis Colon Rectum. 1964 May-Jun;7:211-7 [14159372.001]
  • [Cites] Gut. 2005 Aug;54(8):1194-202 [16009693.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):465-74 [16523446.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):766-70 [17103261.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • (PMID = 19284542.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2657129
  •  go-up   go-down


34. Kehoe SM, Zivanovic O, Ferguson SE, Barakat RR, Soslow RA: Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. Gynecol Oncol; 2010 May;117(2):229-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer.
  • OBJECTIVE: Patients with advanced or recurrent endometrial cancer often have distant metastases found within the lymph nodes, liver, and/or lung.
  • However, there have been reported cases of primary endometrial cancer with metastasis to the bone.
  • The objective of this study was to describe the clinical and pathologic features of endometrial cancer metastatic to bone.
  • METHODS: A retrospective chart review of our clinical and pathology database was performed to identify women diagnosed with endometrial cancer metastatic to the bone between 1990 and 2007.
  • RESULTS: Twenty-one patients with endometrial cancer metastatic to the bone were identified; in 12 patients (57%), the diagnosis was confirmed by a bone biopsy.
  • The median age of diagnosis of primary endometrial cancer was 60 years (range, 32-84).
  • The overall survival of those patients with bone metastases at primary diagnosis was 17 months (95% CI: 2-32) compared to 32 months (95% CI: 14-49) for those with a recurrent bone metastasis.
  • CONCLUSION: Although a rare event, endometrial cancer can metastasize to the bone.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20199802.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Canney PA, Machin MA, Curto J: A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer; 2006 Nov;42(16):2751-6
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer.
  • BACKGROUND: This was a feasibility study of the combination of Exemestane and the cyclooxygenase-2 (COX-2) inhibitor Celecoxib in advanced breast cancer.
  • PATIENTS AND METHODS: Post-menopausal women with histologically proven, hormone receptor positive, advanced breast cancer who had progressive disease, normal blood counts, liver and renal function were eligible.
  • The primary end-point was the percentage of patients who had neither discontinued therapy nor progressed at 6 months ('treatment successes').
  • [MeSH-minor] Adult. Aged. Androstadienes / administration & dosage. Androstadienes / adverse effects. Celecoxib. Cyclooxygenase 2 Inhibitors / administration & dosage. Cyclooxygenase 2 Inhibitors / adverse effects. Disease-Free Survival. Feasibility Studies. Female. Humans. Middle Aged. Postmenopause. Pyrazoles / administration & dosage. Pyrazoles / adverse effects. Quality of Life. Sulfonamides / administration & dosage. Sulfonamides / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. EXEMESTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027257.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; 107868-30-4 / exemestane; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


36. Bjarnason GA, Charpentier D, Wong R, Goel R, Douglas L, Walsh W, Matthews S, Dent S, Seymour L, Winquist E: Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). Invest New Drugs; 2005 Jan;23(1):51-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).
  • BACKGROUND: The primary objective of this Phase I study was to determine the maximum tolerated dose (MTD) and recommended phase II dose for Tomudex and Doxorubicin when given in combination to patients with advanced metastatic cancer.
  • All 4 responding patients and 10 patients with stable disease had gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Head and Neck Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Doxorubicin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Quinazolines / administration & dosage. Salvage Therapy. Thiophenes / administration & dosage

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2005 Aug;23(4):377. Winquist, Eric [added]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1277-82 [7577036.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):541-8 [1548519.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1925-31 [10864199.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):724-5 [8664196.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1407-10 [11762812.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1799-803 [3783204.001]
  • [Cites] Eur J Cancer. 1999 Mar;35 Suppl 1:S14-8 [10645209.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):827-31 [2016625.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):478-86 [11872339.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):7-18 [1898639.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):628-30 [8931686.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):479-81 [8695369.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(1):71-6 [9619761.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1188-93 [9820178.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • (PMID = 15528980.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; 80168379AG / Doxorubicin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


37. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G: Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist; 2010;15(3):285-92
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
  • PATIENTS AND METHODS: Key eligibility criteria included unresectable or metastatic HCC, no prior systemic anticancer treatment, measurable disease, and Child-Pugh class A or mild Child-Pugh class B liver dysfunction.
  • The primary endpoint was progression-free survival at 12 weeks (PFS12).
  • CONCLUSION: Continuous SU treatment with 37.5 mg daily is feasible and has moderate activity in patients with advanced HCC and mild to moderately impaired liver dysfunction.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4068-75 [19652072.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7669-74 [11606410.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):290-6 [11668511.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Clin Biochem. 2003 Nov;36(8):585-90 [14636871.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20 [14762851.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1753-9 [17470865.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2330-1 [17538098.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):1-14 [18176955.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2992-8 [18565886.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1312-27 [18821591.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):446-52 [19064965.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3027-35 [19470923.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):1959-68 [19282169.001]
  • [Cites] Oncologist. 2009 Jul;14(7):717-25 [19581525.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):794-800 [19586800.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 20203173.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00699374
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC3227954
  •  go-up   go-down


38. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2008 Jan;19(1):115-22
Hazardous Substances Data Bank. DIPHENHYDRAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.
  • Primary end point was overall survival (OS).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938425.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; 80061L1WGD / Cimetidine; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


39. Tabata M, Kozuki T, Ueoka H, Kiura K, Harita S, Tada A, Shibayama T, Takigawa N, Yonei T, Gemba K, Segawa Y, Kishino D, Tada S, Hiraki S, Tanimoto M, Okayama Lung Cancer Study Group: A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol; 2007 Jun;60(1):53-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
  • PURPOSE: We conducted a phase I/II study of triplet chemotherapy consisting of cisplatin (CDDP), docetaxel (DCT) and gemcitabine (GEM) in patients with advanced non-small-cell lung cancer (NSCLC).
  • In the phase I portion, a dose escalation study of GEM with starting dose of 400 mg/m(2) was conducted and primary objective in the phase II portion was response rate.
  • RESULTS: The maximally tolerated dose (MTD) and recommended dose (RD) of GEM were determined as 800 mg/m(2) because grade 3 non-hematological toxicity (liver damage, diarrhea, and fatigue) developed in three of nine patients evaluated at that dose level.
  • CONCLUSION: These results indicate that this triplet chemotherapy is feasible and effective in patients with advanced NSCLC.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / pharmacokinetics. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacokinetics. Dose-Response Relationship, Drug. Female. Humans. Leukopenia / chemically induced. Male. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / pharmacokinetics. Treatment Outcome. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009034.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD: Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer; 2008 Jun;60(3):374-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
  • OBJECTIVE: To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks), antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h continuous i.v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC).
  • PFR (primary efficacy endpoint) and objective response rate (secondary efficacy endpoint) were evaluated according to RECIST, while the toxic profile of plitidepsin was assessed using the NCI-CTC, version 2.0.
  • RESULTS: A total of 21 patients with a median age of 61 years and with locally advanced or metastatic non-resectable NSCLC, who had previously received only one line of chemotherapy in an advanced setting, received a total of 54 cycles of treatment (median of two cycles per patient; range: 1-8).
  • One patient was responder for the primary (PFR at 13+/-1 weeks) and secondary efficacy endpoint (stable disease according to RECIST).
  • Other two patients were non-responders for the primary efficacy endpoint, but had stable disease (not confirmed at weeks 13+/-1 due to previous withdrawal due to adverse events).
  • The most common side effects were anemia, and asymptomatic and non-cumulative increases of gamma-glutamyltransferase (GGT) and liver transaminase levels.
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Animals. Disease Progression. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Transaminases / blood. gamma-Glutamyltransferase / blood


41. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP: Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res; 2007 Mar 15;13(6):1769-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
  • PURPOSE: The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week.
  • Grade 3/4 toxicities seen in >5% of patients were reversible elevations of liver enzymes (47%), nausea (9%), vomiting (9%), and headache (5%).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2007 Mar 15;13(6):1625-9 [17363512.001]
  • (PMID = 17363531.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01-CA099168; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / P30 CA47904; United States / NCRR NIH HHS / RR / 5 M01 RR00056; United States / NCI NIH HHS / CA / U01-CA69855
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP70 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 4GY0AVT3L4 / tanespimycin
  •  go-up   go-down


42. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD, MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren): Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1487-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
  • PURPOSE: To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer.
  • METHODS AND MATERIALS: Patients with rectal cancer (clinical stage T3/4 or N+) were scheduled to receive cetuximab (400 mg/m(2) Day 1, 250 mg/m(2) Days 8, 15, 22, 29) in combination with weekly irinotecan 40 mg/m(2) and capecitabine 500 mg/m(2) twice daily (Days 1-38).
  • Primary endpoint was toxicity, and antitumor activity as assessed by the pathologic complete remission (pCR) rate was a secondary endpoint.
  • Main adverse events Grades 2/3/4 were (National Cancer Institute common toxicity criteria version 3.0, %): leukocytopenia 6/2/2, nausea/vomiting 4/2/0, diarrhea 34/30/0, proctitis 26/2/0, elevation of liver transaminases 8/10/0, and acnelike skin rash 46/6/0.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Capecitabine. Cetuximab. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Diarrhea / etiology. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Leukopenia / etiology. Lymphatic Metastasis. Male. Middle Aged. Nausea / etiology. Proctitis / etiology. Remission Induction. Vomiting / etiology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131187.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


43. Mentha G, Roth AD, Terraz S, Giostra E, Gervaz P, Andres A, Morel P, Rubbia-Brandt L, Majno PE: 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg; 2008;25(6):430-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases.
  • BACKGROUND: In patients with synchronous colorectal liver metastases, an approach reversing the traditional therapeutic order - i.e. starting with chemotherapy first, doing the liver surgery second, and performing the colorectal surgery last - is theoretically appealing as it avoids the risk of metastatic progression during treatment of the primary tumor.
  • PATIENTS AND METHODS: 35 patients with advanced synchronous colorectal metastases and nonobstructive colorectal tumors were treated with the reversed approach.
  • Five patients could not complete the program (one death from sepsis during chemotherapy, 3 cases of progressive disease under treatment, and one case of vanishing liver metastases).
  • The remaining 30 patients responded and underwent R0 liver resections with no major complications.
  • Potential problems, in particular regrowth of vanishing metastases and primary tumors, chemotherapy-associated liver damage, and large bowel obstruction, can be minimized by careful multidisciplinary selection, planning and execution.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Colectomy / methods. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome


44. Ziarkiewicz-Wroblewska B, Gornicka B, Suleiman W, Wroblewski T, Morton M, Wilczynski GM, Heleniak H, Skwarek A, Koperski L, Dudek K, Krawczyk M, Jedrzejczak WW, Dwilewicz-Trojaczek J, Wasiutynski A: Primary lymphoma of the liver -- morphological and clinical analysis of 6 cases. Success of aggressive treatment. Neoplasma; 2005;52(3):267-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the liver -- morphological and clinical analysis of 6 cases. Success of aggressive treatment.
  • Histological, clinical and immunohistochemical analysis of 6 cases of primary liver lymphomas (PLL) are presented.
  • PLL represents 4.3% of primary malignant liver tumors diagnosed in our department.
  • There were no signs of scirrhosis, and cancer markers were normal.
  • Despite clinically advanced stage at the time of diagnosis, if treated appropriately, the primary lymphoma of the liver has relatively good prognosis (five of our patients are alive).
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD59 / metabolism. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Stem Cell Transplantation. bcl-2-Associated X Protein


45. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol; 2009 Feb 20;27(6):843-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
  • PATIENTS AND METHODS: Patients who had advanced HCC that was not amenable to surgical or regional therapies, up to one prior systemic treatment; Childs-Pugh score A or B liver function; Eastern Cooperative Oncology Group performance status 0, 1, or 2 received B 10 mg/kg every 14 days and E 150 mg orally daily, continuously, for 28-day cycles.
  • RESULTS: The primary end point of PFS16 was 62.5%.
  • CONCLUSION: The combination of B + E in patients who had advanced HCC showed significant, clinically meaningful antitumor activity.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Drug Therapy, Combination. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 20;27(6):833-5 [19139428.001]
  • [ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263. Lin, Elinor [corrected to Lin, E]
  • (PMID = 19139433.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


46. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA; 2008 Nov;14(11):2348-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
  • To investigate the global expression profile of miRNAs in primary breast cancer (BC) and normal adjacent tumor tissues (NATs) and its potential relevance to clinicopathological characteristics and patient survival, the genome-wide expression profiling of miRNAs in BC was investigated using a microarray containing 435 mature human miRNA oligonucleotide probes.
  • Interestingly, among the 113 BC cases, high level expression of miR-21 was significantly correlated with advanced clinical stage (P = 0.006, Fisher's exact text), lymph node metastasis (P = 0.007, Fisher's exact text), and shortened survival of the patients (hazard ratio [HR]=5.476, P < 0.001).
  • This study could identify the differentiated miRNAs expression profile in BC and reveal that miR-21 overexpression was correlated with specific breast cancer biopathologic features, such as advanced tumor stage, lymph node metastasis, and poor survival of the patients, indicating that miR-21 may serve as a molecular prognostic marker for BC and disease progression.
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Mar;18(3):350-9 [18270520.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):137-42 [11417963.001]
  • [Cites] Bioinformatics. 2001;17 Suppl 1:S49-55 [11472992.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):408-17 [12219783.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):923-9 [12648972.001]
  • [Cites] Cell. 2003 Jun 13;113(6):673-6 [12809598.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer. 2005 May 1;103(9):1770-7 [15770691.001]
  • [Cites] Nat Methods. 2004 Oct;1(1):47-53 [15782152.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):155-61 [15782179.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] Nat Med. 2005 Jul;11(7):712-4 [16015356.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] RNA. 2006 May;12(5):913-20 [16540696.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):438-40 [17152490.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]
  • [Cites] BMC Biotechnol. 2007;7:36 [17603869.001]
  • (PMID = 18812439.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN21 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2578865
  •  go-up   go-down


47. Burcoveanu C, Stefan S, Ursache A, Pricop A: [Primary and secondary hepatic cancer--specifics of surgical treatment in correlation with disease stage]. Rev Med Chir Soc Med Nat Iasi; 2009 Oct-Dec;113(4):1131-5
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary and secondary hepatic cancer--specifics of surgical treatment in correlation with disease stage].
  • Given the necessity of increasing their resectability, there are evaluated the possibilities of surgical treatment for these types of hepatic cancer, in the context of dominant clinical presence of advanced hepatic tumors.
  • MATERIAL AND METHOD: The study comprises 190 patients during 01.01.2000-31.12.2007, in the IIIrd Surgical Clinic, Iaşi, with primary and secondary hepatic tumors.
  • [MeSH-major] Anti-Infective Agents, Local / administration & dosage. Catheter Ablation. Ethanol / administration & dosage. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191887.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 3K9958V90M / Ethanol
  •  go-up   go-down


48. Ikeda O, Kusunoki S, Kudoh K, Takamori H, Tsuji T, Kanemitsu K, Yamashita Y: Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma. Cardiovasc Intervent Radiol; 2006 May-Jun;29(3):362-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma.
  • PURPOSE: To evaluate the effects of combined continuous transcatheter arterial infusion (CTAI) and systemic chemotherapy in patients with advanced pancreatic carcinoma.
  • METHODS: CTAI was performed in 17 patients with stage IV pancreatic cancer with (n = 11) or without (n = 6) liver metastasis.
  • Treatment effects were evaluated based on the primary tumor size, liver metastasis, and survival time and factors such as tumor size, tumor location, and stage of pancreatic carcinoma; the embolized arteries were analyzed with respect to treatment effects and prognosis.
  • CT showed a decrease in tumor size in 6 of 17 (35%) patients and a decrease in liver metastases in 6 of 11 (55%) patients.
  • CONCLUSION: In patients with advanced pancreatic cancer, long-term CTAI with systemic chemotherapy appeared to be effective not only against the primary tumor but also against liver metastases.
  • [MeSH-minor] Adult. Aged. Angiography. Chi-Square Distribution. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Radiography, Interventional. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16502181.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


49. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS: Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer; 2005 Dec 15;104(12):2753-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
  • BACKGROUND: Biliary tract carcinoma is an aggressive cancer, with median survival rarely exceeding 6 months.
  • A Phase II trial was conducted to study a combination of oral capecitabine and gemcitabine (CapGem) as first-line therapy in patients with advanced and/or metastatic biliary carcinoma.
  • Primary tumor sites were: intrahepatic (n = 14) and extrahepatic biliary duct (n = 16); gallbladder (n = 7); and ampulla (n = 7).
  • CONCLUSIONS: CapGem is an active and well tolerated first-line combination chemotherapy regimen for patients with advanced/metastatic biliary tract carcinoma that offers a convenient home-based therapy.
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bone Neoplasms / secondary. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16294346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A: Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer; 2010 Apr;46(6):1026-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients.
  • INTRODUCTION: Due to advanced chemotherapy regimens, patients presenting with residual liver metastases of colorectal cancer (CRC) has increased.
  • We investigated in a selected patient cohort local control of liver metastasis from CRC using robotic radiosurgery.
  • METHODS AND MATERIALS: In this study patients with colorectal liver metastases were prospectively followed after having been treated with single-session radiosurgery using a robotic image-guided device and real-time tumour tracking.
  • The primary end-point was local control (LC); secondary end-points were toxicity, progression-free survival (PFS) and overall survival (OS).
  • Follow up was done by liver MRI every 3 months post-treatment.
  • RESULTS: Fourteen patients (median age 65 years), with a total of 19 colorectal liver metastases were treated with 24 Gy in one fraction.
  • DISCUSSION: Frameless robotic image-guided radiosurgery with real-time tumour tracking as an effective treatment for patients with colorectal liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / surgery. Radiosurgery / methods. Robotics / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Surgery, Computer-Assisted / instrumentation. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20153959.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Mayer F, Aebert H, Rudert M, Königsrainer A, Horger M, Kanz L, Bamberg M, Ziemer G, Hartmann JT: Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. Oncologist; 2007 Sep;12(9):1134-42
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience.
  • METHODS: Between January 1993 and September 2006, of 1,429 patients registered to the Sarcoma Center, 14 had a primary sarcoma of the heart or large vessels.
  • Six patients presented with distant metastases to the lungs (n = 5), lymph nodes (n = 2), and liver (n = 1).
  • CONCLUSIONS: Patients with primary sarcomas of the heart and the large vessels were of a young age, and more than half of them presented with advanced disease.
  • Given the promising response to chemotherapy, an optimized treatment approach including neoadjuvant chemo-/radiotherapy in patients with locally advanced disease should be pursued.
  • [MeSH-minor] Adult. Aortic Diseases / epidemiology. Female. Follow-Up Studies. Germany / epidemiology. Hemangiosarcoma / epidemiology. Humans. Leiomyosarcoma / epidemiology. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy / statistics & numerical data. Pulmonary Artery / pathology. Remission Induction. Retrospective Studies. Survival Rate. Venae Cavae / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914083.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer; 2010 Aug;46(12):2206-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
  • PATIENTS AND METHODS: Patients with advanced head and neck, breast and ovarian cancer, soft tissue sarcoma and melanoma were selected according to protocol-defined general and tumour-specific criteria.
  • They were 18years old, had a good performance status, adequate bone marrow, renal and liver function, measurable progressive disease and had completed other relevant systemic treatments >4weeks ago.
  • The rate of objective responses (RECIST criteria) was chosen as primary end-point.
  • RESULTS: Seventy six patients were included, 71 started treatment and received a median number of two cycles (four in ovarian cancer).
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Feasibility Studies. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Humans. Infusions, Intravenous. Male. Melanoma / drug therapy. Melanoma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Patient Compliance. Sarcoma / drug therapy. Sarcoma / metabolism. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20471824.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BI 2536; 0 / Pteridines
  •  go-up   go-down


53. Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS, Park SY: The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol; 2009 Jan;112(1):28-34
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer.
  • OBJECTIVE: The objective of this study was to determine the clinical significance of hepatic parenchymal metastasis on survival in patients with advanced epithelial ovarian cancer.
  • METHODS: We conducted a retrospective review of ovarian cancer patients with stages IIIc and IV hepatic parenchymal metastasis who were treated at the National Cancer Center in Korea between January 2001 and January 2008.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2009 Nov;115(2):319; author reply 319-20 [19446315.001]
  • (PMID = 19010521.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Young A, Madi A, Treanor D, Millson C, Selby P, Chester J: Fulminant hepatic failure in a patient with advanced extragonadal germ cell tumour. BMJ Case Rep; 2010;2010
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant hepatic failure in a patient with advanced extragonadal germ cell tumour.
  • Fulminant hepatic failure (FHF) in association with metastatic cancer, without evidence of liver metastases, has not been previously reported in the literature.
  • This report concerns a case of FHF in a 36-year-old man with advanced germ cell tumour arising from an extragonadal (retroperitoneal) primary.
  • Liver function and encephalopathy improved following chemotherapy, suggesting prompt diagnosis and treatment may have cured the patient.
  • [MeSH-major] Liver Failure, Acute / etiology. Retroperitoneal Neoplasms / complications. Seminoma / complications
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Humans. Liver / pathology. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Apr 21;12(15):2466-8 [16688847.001]
  • [Cites] J Gen Intern Med. 2006 Jul;21(7):C11-3 [16808761.001]
  • [Cites] N Engl J Med. 1993 Dec 16;329(25):1862-72 [8305063.001]
  • [Cites] Postgrad Med J. 2005 Mar;81(953):148-54 [15749789.001]
  • [Cites] Turk J Gastroenterol. 2004 Mar;15(1):53-5 [15264123.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):804-7 [6589032.001]
  • [Cites] Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii5-viii8 [17890263.001]
  • [Cites] Cancer Invest. 2002;20(7-8):1105-13 [12449743.001]
  • (PMID = 22778367.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC3027936
  •  go-up   go-down


55. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Rentsch M, Muacevic A: Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Ann Surg Oncol; 2010 Nov;17(11):2877-83
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors.
  • BACKGROUND: The treatment of isolated liver metastases has become a rapidly developing field with many new, technically advanced methods.
  • Here we present the therapeutic efficacy of a robotic radiosurgery for local control of liver metastases from solid tumors.
  • METHODS: Patients with tumorous lesions to the liver, not qualifying for surgery, were treated with single-session radiosurgery (24 Gy) that used robotic image-guided real-time tumor tracking.
  • Metastases originated from colon cancer (n = 19), ovarian cancer (n = 3), pancreatic cancer (n = 2), breast cancer (n = 2), and others (n = 6).
  • Four lesions were of primary liver origin (hepatocellular carcinoma and cholangiocellular carcinoma).
  • CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver neoplasm is a new and promising approach for patients with disease that is not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.
  • [MeSH-major] Liver Neoplasms / surgery. Radiosurgery. Robotics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574773.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Lee KH, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, Kim HK, Lee MA, Im SA, Chang HM, Cho JY, Zang DY, Kim BS, Kim JS: Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemother Pharmacol; 2009 Jul;64(2):317-25
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
  • PURPOSE: Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC).
  • METHODS: This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma.
  • The primary end point was response rate (RR).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Quality of Life. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19034448.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


57. Sakai Y, Saotome T, Fujimori M, Shimizu S, Inkyo T, Yugeta H, Ohbu M, Koma Y, Sato T, Nagashima F, Hayasaka A, Fukuyama Y, Tsuchiya S, Tsuyuguchi T, Saisho H: [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1319-22
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].
  • We performed a pilot study of combination chemotherapy with TS-1 and cisplatin for highly advanced gastric cancer.
  • From June 2002, 12 patients with multiple liver metastases, carcinomatous lymphangitis or peritoneal dissemination, were enrolled in the study.
  • An objective response was obtained in 9 cases (75.0%) of primary sites and 6 cases of metastatic sites.
  • The TS-1/CDDP regimen had almost no survival benefits, but may induce relief of symptoms due to cancer and better quality of life.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pilot Projects. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184932.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


58. Siriwardana RC, Wijesuriya SR, Kumarage SK, Deen KI: Synchronous liver metastasis in colorectal cancer in Sri Lanka. Indian J Gastroenterol; 2010 Jul;29(4):149-51
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous liver metastasis in colorectal cancer in Sri Lanka.
  • OBJECTIVE: To assess the incidence of synchronous colorectal liver metastasis in patients referred to a tertiary referral center in Sri Lanka and to evaluate the differences in the clinicopathological features of patients with and without synchronous metastasis.
  • In the two groups macroscopic features compared were: tumor size (2 cm, 2-5 cm, and >5 cm), site of primary tumor and side of liver involved.
  • RESULTS: The rectum was the primary site of the tumor in a majority (60%) of patients.
  • There was no difference in the distribution of the primary site and size of the tumor, pathological stage, lymphatic infiltration and the degree of tumor differentiation in two groups (p > 0.05).
  • CONCLUSION: The incidence of synchronous colorectal liver metastasis seems to be lower in our patients.
  • Association of higher CEA level, advanced nodal stage and presence of vascular invasion needs to be further assessed with risk of developing metachronous liver metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Sri Lanka / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):786-94 [17103254.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Sep;6(9):1016-21 [18558515.001]
  • [Cites] Ceylon Med J. 2008 Mar;53(1):17-21 [18590265.001]
  • [Cites] Colorectal Dis. 2009 Sep;11(7):745-9 [19708093.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):465-74 [16523446.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • (PMID = 20740338.001).
  • [ISSN] 0975-0711
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


59. Tsai JS, Wu CH, Chiu TY, Hu WY, Chen CY: Symptom patterns of advanced cancer patients in a palliative care unit. Palliat Med; 2006 Sep;20(6):617-22
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom patterns of advanced cancer patients in a palliative care unit.
  • This study involved longitudinal evaluations of symptom severity and describes the symptom patterns of 77 terminal cancer patients (median age: 62 years; 61% female), selected from 537 consecutive patients admitted to the Palliative Care Unit of the National Taiwan University Hospital.
  • The most common primary cancer sites in these patients were lung (23.4%), liver (15.6%), and stomach (13%).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Severity of Illness Index. Taiwan / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060255.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


60. Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol; 2009 Feb;32(1):38-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
  • BACKGROUND: The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy.
  • METHODS: The study population consisted of 70 patients with advanced colorectal cancer (median age, 54 years).
  • The expression of ERCC1, TS, and GSTpi in primary tumors was examined using immunohistochemistry.
  • CONCLUSION: Immunohistochemical study of ERCC1 and TS may be useful for the prediction of clinical outcome in patients with advanced colorectal cancer treated with 5-FU and oxaliplatin.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. DNA Repair. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Immunoenzyme Techniques. Liver Neoplasms / drug therapy. Liver Neoplasms / enzymology. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / enzymology. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194123.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; EC 2.1.1.45 / Thymidylate Synthase; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Trahair T, Andrews L, Cohn RJ: Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. Pediatr Blood Cancer; 2007 Mar;48(3):345-8
Genetic Alliance. consumer health - Li Fraumeni syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma.
  • A contemporaneous presentation of a second breast cancer in a mother and an extremity rhabdomyosarcoma (RMS) in her daughter led to the diagnosis of the Li Fraumeni syndrome (LFS).
  • After reviewing the literature about the natural history of the LFS 2, the incidence of second malignancy (SMN) in RMS survivors 3-6 and the management of extremity RMS 7-9, we are concerned that contemporary RMS treatment, combining non-mutilating surgery with chemoradiotherapy, may be associated with an excessive SMN risk in LFS patients with advanced RMS.
  • [MeSH-minor] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Adult. Antineoplastic Agents / therapeutic use. Astrocytoma / genetics. Astrocytoma / surgery. Breast Neoplasms / genetics. Carcinoma / genetics. Case Management. Child, Preschool. Codon, Nonsense. Esophageal Neoplasms / genetics. Female. Humans. Leg. Liver Neoplasms / genetics. Male. Neoplasms, Radiation-Induced / prevention & control. Neoplasms, Second Primary / prevention & control. Pedigree. Radiotherapy, Adjuvant / contraindications. Retroperitoneal Neoplasms / genetics. Retroperitoneal Neoplasms / surgery. Sarcoma / genetics. Sarcoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16534790.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Codon, Nonsense
  •  go-up   go-down


62. Takahashi T, Itoh Y: [Effect on neoadjuvant chemotherapy using s-1 for unresectable liver metastasis from rectal cancer-a case report]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2669-72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect on neoadjuvant chemotherapy using s-1 for unresectable liver metastasis from rectal cancer-a case report].
  • The patient was a 42-year-old female who had advanced rectal cancer(Ra, type 2)with liver metastasis.
  • The preoperative diagnosis was T2N1H2, but the liver tumor was unresectable for hepatic vein invasion in September, 2004.
  • She underwent low anterior resection for primary rectal cancer at first after she was given S-1 80 mg/day(14 days)for a histological effect judgment.
  • Because CT showed reduction of liver metastasis after the operation, she was treated with 2 courses of chemotherapy using S-1.
  • Radiographic examination showed reduction of liver metastasis(36%)and improvement of hepatic vein invasion.
  • We experienced this case in which preoperative S-1 proved effective for liver metastasis from rectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / therapeutic use. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Oxonic Acid / therapeutic use. Rectal Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Drug Combinations. Female. Hepatectomy. Humans. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009478.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


63. Suzuki S, Sasajima K, Sato Y, Watanabe H, Matsutani T, Iida S, Hosone M, Tsukui T, Maeda S, Shimizu K, Tajiri T: MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer. Br J Cancer; 2008 Jul 22;99(2):350-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer.
  • Tumour samples from 71 patients with stomach cancer, 41 patients with liver metastasis (group A) and 15 patients each in stages II-IV (group B) and stage I (group C) without liver metastasis were analysed.
  • MAGE-A10 mRNA expression in liver metastasis was found in eight (88.9%) out of nine patients.
  • The concordant rate between MAGE-A family protein expression and MAGE-A10 mRNA expression in the primary sites was 81.7% (P<0.0001).
  • The results of this study suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Neoplasm Proteins / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / chemistry. Disease Progression. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Male. Melanoma-Specific Antigens. Middle Aged. RNA Probes. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):838-43 [14970862.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Immunogenetics. 1994;40(5):360-9 [7927540.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1522-5 [7557134.001]
  • [Cites] J Surg Oncol. 1997 Mar;64(3):195-201 [9121149.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5A):3559-63 [9413202.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6849-54 [10352307.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):975-7 [10425289.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):901-7 [10446460.001]
  • [Cites] Cancer Immun. 2004 Nov 1;4:11 [15516106.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):27-39 [15621988.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1709-16 [15661935.001]
  • [Cites] Cancer Lett. 2005 Mar 10;219(2):223-32 [15723723.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3080-6 [15728523.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):419-24 [15998815.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2105-11 [16158951.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8055-62 [16299236.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):189-95 [16432351.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1089-98 [16596224.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4693-700 [16651421.001]
  • [Cites] Pathol Int. 2006 Sep;56(9):510-5 [16930331.001]
  • [Cites] J Immunother. 2006 Sep-Oct;29(5):499-511 [16971806.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):337-43 [17066423.001]
  • [Cites] J Invest Dermatol. 2007 Feb;127(2):267-75 [16960553.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):839-47 [16960690.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4355-9 [17671116.001]
  • [Cites] Arch Histol Cytol. 2007 Jul;70(2):127-34 [17827670.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Oncology. 2000 Aug;59(2):145-51 [10971174.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):869-73 [11314020.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5850-6 [11479225.001]
  • [Cites] J Clin Invest. 2002 Dec;110(12):1813-22 [12488431.001]
  • [Cites] Oncology. 2003;65(2):95-101 [12931013.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5601-6 [14500401.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • (PMID = 18594524.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / MAGE-A10 antigen; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA Probes; 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC2480964
  •  go-up   go-down


64. Tamura S, Miki H, Nakata K, Takiuchi D, Okada K, Nakahira S, Okamura S, Sugimoto K, Tomita N, Takatsuka Y: Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. Gastric Cancer; 2007;10(4):251-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
  • We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1.
  • He was diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy.
  • After five courses, primary tumor reduction was confirmed and no cancer cells were detected on pathocytological investigation at second-look laparoscopy.
  • He died from liver metastasis 29 months after the initial treatment, but he had not suffered from peritoneal metastases and had kept a good quality of life (QOL) since that treatment.
  • This chemotherapy can be applied as one of the promising candidates for the treatment of patients with peritoneal metastasis of gastric cancer.
  • [MeSH-minor] Administration, Oral. Adult. Antineoplastic Agents / administration & dosage. Drug Combinations. Humans. Hydronephrosis / complications. Infusions, Parenteral. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1993 Mar-Apr;17(2):256-61; discussion 261-2 [8511923.001]
  • [Cites] Oncology. 2003;64(2):176-82 [12566916.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Nov;29(12):2164-7 [12484028.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Cancer Lett. 2004 Jul 16;210(2):189-96 [15183534.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):811-5 [12066214.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Oncology. 1993 Sep-Oct;50(5):338-43 [8378028.001]
  • [Cites] Gastric Cancer. 2001;4(2):75-82 [11706764.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4093-100 [2898289.001]
  • [Cites] Oncology. 2000 Feb;58(2):96-107 [10705236.001]
  • (PMID = 18095081.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


65. Wu XM, Hu CZ, Li N, Zhu JQ, Wu YF: [Relationship of serum level of creatine kinase of MB type to cardiac function of patients with advanced tumors and its prognostic value]. Ai Zheng; 2005 Apr;24(4):506-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship of serum level of creatine kinase of MB type to cardiac function of patients with advanced tumors and its prognostic value].
  • BACKGROUND & OBJECTIVE: Patients with advanced tumors usually suffer from cardiac dysfunction.
  • This study was to estimate relationship of serum level of CK-MB to cardiac function of patients with advanced tumors, and its prognostic value.
  • METHODS: Serum CK-MB in 68 patients with advanced tumors was detected by immunoinhibition assay.
  • Elevation of serum CK-MB was frequently found in patients with primary liver cancer or liver metastasis (P < 0.05).
  • Serum level of CK-MB may be a predictor of poor prognosis of patients with advanced tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / blood. Breast Neoplasms / physiopathology. Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / physiopathology. Female. Heart Function Tests. Humans. Liver Neoplasms / blood. Liver Neoplasms / physiopathology. Lung Neoplasms / blood. Lung Neoplasms / physiopathology. Male. Middle Aged. Neoplasm Staging. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820080.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.3.2 / Creatine Kinase, MB Form
  •  go-up   go-down


66. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, Oblimersen Melanoma Study Group: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol; 2006 Oct 10;24(29):4738-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
  • We evaluated whether targeting Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma.
  • PATIENTS AND METHODS: We randomly assigned chemotherapy-naïve patients with advanced melanoma to treatment with dacarbazine (1,000 mg/m2) alone or preceded by a 5-day continuous intravenous infusion of oblimersen sodium (7 mg/kg/d) every 3 weeks for up to eight cycles.
  • Patients were stratified by Eastern Cooperative Oncology Group performance status, liver metastases, disease site, and serum lactate dehydrogenase (LDH).
  • The primary efficacy end point was overall survival.
  • CONCLUSION: The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients without an elevated baseline serum LDH.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Oligonucleotides, Antisense / therapeutic use. Proto-Oncogene Proteins c-bcl-2. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Jun 1;25(16):e20-1 [17538155.001]
  • [CommentIn] J Clin Oncol. 2006 Oct 10;24(29):4673-4 [16966683.001]
  • (PMID = 16966688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Thionucleotides; 7GR28W0FJI / Dacarbazine; 85J5ZP6YSL / oblimersen; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


67. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol; 2009 Jun 20;27(18):3027-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
  • PURPOSE: To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response.
  • PATIENTS AND METHODS: We conducted a multidisciplinary phase II study of sunitinib, an antivascular endothelial growth factor receptor tyrosine kinase inhibitor, in advanced HCC.
  • The primary end point was progression-free survival (PFS).
  • CONCLUSION: Sunitinib shows evidence of modest antitumor activity in advanced HCC with manageable adverse effects.
  • Our study suggests that control of inflammation might be critical for improving treatment outcome in advanced HCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers / blood. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemokine CXCL12 / blood. Female. Humans. Interleukin-6 / blood. Magnetic Resonance Imaging. Male. Middle Aged. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Oncologist. 2006 Jul-Aug;11(7):790-800 [16880238.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):204-8 [17359908.001]
  • [Cites] Nat Protoc. 2007;2(4):805-10 [17446880.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Nat Biotechnol. 2007 Aug;25(8):911-20 [17664940.001]
  • [Cites] Trends Mol Med. 2008 Mar;14(3):109-19 [18261959.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4672-8 [18824714.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gut. 2001 Jan;48(1):87-96 [11115828.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Nat Med. 2003 Jun;9(6):789-95 [12740570.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3955-64 [14517187.001]
  • [Cites] Br J Radiol. 2003;76 Spec No 1:S83-6 [15456717.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3004-9 [8674055.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):3-23 [15757802.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G571-8 [15860640.001]
  • [Cites] Oncology. 2005;69(5):363-71 [16319507.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [CommentIn] J Clin Oncol. 2009 Dec 10;27(35):e248-50; author reply e251-2 [19901099.001]
  • (PMID = 19470923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR001066; United States / NCI NIH HHS / CA / P01 CA080124; United States / NCI NIH HHS / CA / P01 CA80124; United States / NCI NIH HHS / CA / K23 CA139005; United States / NCRR NIH HHS / RR / M01-RR-01066; United States / NCI NIH HHS / CA / R01 CA115767
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Chemokine CXCL12; 0 / Indoles; 0 / Interleukin-6; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC2702235
  •  go-up   go-down


68. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol; 2005 Aug 20;23(24):5795-804
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
  • This study is based on the European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease.
  • RESULTS: Initial resistance was recorded for 116 (12%) of 934 assessable patients and was independently predicted by the presence of lung and absence of liver metastases, low hemoglobin level, and high granulocyte count.
  • Among 818 patients who were alive and progression free at 3 months, 347 subsequent progressions were recorded, and late resistance was independently predicted by high baseline granulocyte count, primary tumor outside of the stomach, large tumor size, and low initial imatinib dose.
  • [MeSH-minor] Adult. Aged. Benzamides. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Imatinib Mesylate. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110036.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Obayashi K, Ohwada S, Sunose Y, Yamamoto K, Igarashi R, Hamada K, Takeyoshi I, Horiuchi R: [Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1915-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas].
  • Gemcitabine(GEM)is the standard therapy for advanced pancreatic cancer.
  • GEM-oxaliplatin (GEMOX) combination treatment has been reported to be superior to GEM alone in terms of clinical progression-free survival, but it is not the therapy of choice for pancreatic cancer.
  • We report a case of advanced mucinous cystic neoplasm (MCN) of the pancreas with multiple hepatic metastases in a 39-year-old female.
  • When the hepatic metastases disappeared after 13 courses, the primary MCN was removed surgically after 16 courses of GEMOX treatment.
  • [MeSH-major] Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / pathology. Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011342.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


70. Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B: Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol; 2007 Jan;18(1):64-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
  • RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases.


71. Chen B, Gao L, Xu GZ, Li SY, Huang XD, Yi JL: [Postoperative radiotherapy for primary intraosseous carcinoma of the jaws]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):540-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative radiotherapy for primary intraosseous carcinoma of the jaws].
  • OBJECTIVE: To investigate the indication, location and dose of postoperative radiotherapy for primary intraosseous carcinoma (PIOC) of the jaws.
  • METHODS: From October 1969 to November 2005, 13 patients with PIOC were treated at the Cancer Hospital of Chinese Academy of Medical Sciences.
  • RESULTS: All of the 13 cases in our series had advanced disease, and overall 1-, 2- and 3-year survival rats were 59.2%, 33.8% and 12.7% , respectively.
  • It seemed that surgery plus postoperative radiotherapy could not improve the survival of PIOC patients with involvement of adjacent soft-tissues or positive neck nodes or partial excision of primary tumor when compared with surgery alone, if the bias of selection in the patients for postoperative radiotherapy was neglected.
  • CONCLUSION: Postopreative radiotherapy may improve the survival for the patient with primary intraosseous carcinoma of the jaws.
  • Our suggestion is that postoperative radiotherapy should be applied to the patient with any of the following items: positive operative margin; tumor involvement of adjacent soft-tissues; positive neck nodes; partial excision of primary tumor.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Mandible / surgery. Maxilla / surgery. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


72. Guan-Zhen Y, Ying C, Can-Rong N, Guo-Dong W, Jian-Xin Q, Jie-Jun W: Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer. Int J Exp Pathol; 2007 Jun;88(3):175-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer.
  • PURPOSE: Metastasis remains an incurable common complication in patients with gastric cancer.
  • To compare protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) between primary tumours and metastatic tumours may be useful in illustrating these theories.
  • METHODS: Metastasis-related tissue microarrays (including normal tissues, primary tumours, nodal metastases and liver metastases) were constructed.
  • The protein expression of nm23, KISS1, KAI1 and p53 in lymph node and liver metastases from advanced gastric cancer specimens was mainly examined by immunohistochemical staining in relation to primary tumours.
  • RESULTS: Immunohistochemical staining showed reduced protein expression of nm23, KISS1 and KAI1 in lymph node and liver metastases compared with primary tumours.
  • CONCLUSIONS: Our investigations revealed a tendency of reduced protein expression of metastasis suppressor genes nm23, KISS1 and KAI1 in gastric cancer with the progress of metastasis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD82 / analysis. Antigens, CD82 / genetics. Female. Gene Expression. Gene Expression Profiling. Genetic Markers. Humans. Immunohistochemistry. Kisspeptins. Lymphatic Metastasis. Male. Middle Aged. NM23 Nucleoside Diphosphate Kinases. Nucleoside-Diphosphate Kinase / analysis. Nucleoside-Diphosphate Kinase / genetics. Oligonucleotide Array Sequence Analysis. Staining and Labeling. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1999 Nov;126(5):869-80 [10568187.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1751-5 [8620488.001]
  • [Cites] Oncol Rep. 2000 Jan-Feb;7(1):99-103 [10601600.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3424-9 [10999724.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):499-502 [11095940.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1164-72 [11060311.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):170-4 [11289754.001]
  • [Cites] Nature. 2001 May 31;411(6837):613-7 [11385580.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5284-8 [11431371.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34631-6 [11457843.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):16-23 [11668473.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2001 May;23(3):224-7 [11783092.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):441-51 [12013533.001]
  • [Cites] BMC Cancer. 2001;1:9 [11518545.001]
  • [Cites] Pathology. 2002 Oct;34(5):427-32 [12408341.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):609-17 [12547718.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):11-8 [12650602.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1231-6 [12800230.001]
  • [Cites] J Bioenerg Biomembr. 2003 Feb;35(1):19-30 [12848338.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1257-63 [12883690.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2246-50 [8635091.001]
  • [Cites] J Korean Med Sci. 1995 Dec;10(6):406-13 [8924224.001]
  • [Cites] Am J Gastroenterol. 1997 Jul;92(7):1182-6 [9219795.001]
  • [Cites] Aust N Z J Surg. 1998 Mar;68(3):180-2 [9563444.001]
  • [Cites] Cancer Lett. 1998 Jun 5;128(1):23-9 [9652789.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11307-11 [9736732.001]
  • [Cites] Oncology. 1999;56(2):122-8 [9949298.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):179-84 [10450731.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8 [15592684.001]
  • [Cites] Oncology. 2005;68(2-3):87-96 [15886500.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Sep;129(9):531-5 [12898236.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):97-105 [14568162.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):207-11 [14639604.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1379-83 [14977840.001]
  • [Cites] Pancreas. 2004 May;28(4):421-6 [15097860.001]
  • [Cites] Ann Diagn Pathol. 2004 Feb;8(1):6-16 [15129904.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):868-72 [15300798.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] J Natl Cancer Inst. 1994 Dec 21;86(24):1838-44 [7990158.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5724-31 [10582691.001]
  • (PMID = 17504447.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD82; 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  • [Other-IDs] NLM/ PMC2517304
  •  go-up   go-down


73. Malmström A, Hansen J, Malmberg L, Carlsson L, Svensson JH, Ahlgren J, Ahlin C, Jansson T, Westberg R: Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. Acta Oncol; 2010;49(1):35-41
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
  • AIM: The aim of this study was to explore the clinical value of gemcitabine combined with capecitabine (GC) in heavily pre-treated patients with metastatic breast cancer.
  • In 14 patients (41%), more than two metastatic sites were diagnosed with bone (68%) and liver (62%) being the most prominent.
  • The primary objective was to investigate time to progression.
  • DISCUSSIONS: We investigated the value of the GC combination as a treatment for late stage breast cancer patients.
  • [MeSH-minor] Adult. Aged. Anthracyclines / therapeutic use. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Kaplan-Meier Estimate. Middle Aged. Salvage Therapy. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839920.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Irimie A, Achimas-Cadariu P, Burz C, Puscas E: Multiple primary malignancies--epidemiological analysis at a single tertiary institution. J Gastrointestin Liver Dis; 2010 Mar;19(1):69-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary malignancies--epidemiological analysis at a single tertiary institution.
  • BACKGROUND: A literature review on 1,104 269 cancer patients concluded that the prevalence of multiple primary malignancies (MPM) is between 0.73% and 11.7%.
  • AIM: The purpose of this study was to investigate clinically useful information for effective screening for synchronous and metachronous second primary cancers and to identify a potential surveillance protocol.
  • Both primary and secondary tumors tended to be in an advanced stage explained by the low compliance of the patients to follow-up.
  • Screening procedures are especially useful for the early detection of associated tumors, whereas careful monitoring of patients treated for primary cancer and a good communication between patients and medical care team would ensure an early detection for secondary tumors, and, subsequently, an appropriate management.
  • [MeSH-major] Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Early Detection of Cancer. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Romania / epidemiology. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361078.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


75. Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE, AIO Hepatobiliary Study Group: Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC Cancer; 2010;10:457
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial.
  • BACKGROUND: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials.
  • Between 10/2002 and 03/2005, 135 patients with locally advanced or metastasised HCC (Karnofsky >or=60%/Child-Pugh <or= 12) were randomised to receive thymostimulin 75 mg s.c.
  • 5x/week or placebo stratified according to liver function.
  • Primary endpoint was twelve-month survival, secondary endpoints overall survival (OS), time to progression (TTP), tumor response, safety and quality of life.
  • A subgroup analysis according to liver function, KPS and tumor stage (Okuda, CLIP and BCLC) formed part of the protocol.
  • Adjustment for liver function, Karnofsky status or tumor stage did not affect results.
  • CONCLUSIONS: In our phase III trial, we found no evidence of any benefit to thymostimulin in the treatment of advanced HCC and there is therefore no justification for its use as single-agent treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Interferon Inducers / therapeutic use. Liver Neoplasms / drug therapy. Thymus Extracts / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Double-Blind Method. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Placebos. Prospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1989 Jan-Feb;9(1):193-6 [2539772.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Ann Surg Oncol. 1997 Mar;4(2):149-55 [9084852.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):209-15 [9496515.001]
  • [Cites] Semin Liver Dis. 2005;25(2):201-11 [15918148.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:326-38 [17495242.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:297-304 [17567944.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:357-67 [17600289.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:225-34 [17600290.001]
  • [Cites] BMC Cancer. 2008;8:72 [18366627.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Hepatology. 2002 Mar;35(3):519-24 [11870363.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2229-39 [11980994.001]
  • [Cites] Z Gastroenterol. 2003 Nov;41(11):1101-10 [14648380.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):409-18 [15231247.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Immunopharmacol Immunotoxicol. 1992;14(3):421-37 [1325490.001]
  • (PMID = 20735834.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN64487365
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Inducers; 0 / Placebos; 0 / Thymus Extracts; 0 / thymostimulin
  • [Other-IDs] NLM/ PMC2936330
  • [Investigator] Lesske J; Dollinger MM; Fleig WE; Schoppmeyer K; Mössner J; Nehls O; Gregor M; Welker MW; Zeuzem S; Wiest R; Schoelmerich J; Hummel F; Singer M; Seufferlein T; Adler G; Mohr L; Spangenberg HC; Blum H; Pohl M; Schmiegel W; Gog C; Bechstein W; Schaefer C; Stange E; Lammert F; Matern S
  •  go-up   go-down


76. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol; 2009 Jul 1;27(19):3126-32
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
  • PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in patients with advanced STS.
  • PATIENTS AND METHODS Patients with intermediate- or high-grade advanced STS who were ineligible for chemotherapy or who had received no more than two prior cytotoxic agents for advanced disease, who had documented progression, who had adequate performance status, and who had good organ function were eligible.
  • The primary end point was progression-free rate at 12 weeks (PFR(12 weeks)).
  • Compared with historical controls who were treated with second-line chemotherapy, progression-free and overall survivals were prolonged in the three cohorts in which the primary end point was reached.
  • Other toxicities included liver enzyme elevations, myelosuppression, and proteinuria, all of which were mostly grades 1 to 2.
  • CONCLUSION Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  •  go-up   go-down


77. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, von Kalle C, Schemmer P: Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer; 2008;8:349
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
  • BACKGROUND: Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list.
  • The oral multikinase inhibitor sorafenib significantly increases overall survival and time-to-progression in patients with advanced hepatocellular cancer.
  • Evaluation of time-to-progression as primary endpoint (TTP) will be performed at 120 events.
  • DISCUSSION: As TACE is the most widely used primary treatment of HCC before LTx and sorafenib is the only proven effective systemic treatment for advanced HCC there is a strong rational to combine both treatment modalities.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Double-Blind Method. Female. Humans. Liver Transplantation. Male. Niacinamide / analogs & derivatives. Phenylurea Compounds. Research Design

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2004 Nov;40(16):2439-44 [15519517.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Liver Transpl. 2005 Jul;11(7):767-75 [15973710.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S105-8 [16286885.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1505-14 [16315294.001]
  • [Cites] Liver Transpl. 2006 Apr;12(4):665-73 [16482577.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Liver Transpl. 2003 Jun;9(6):557-63 [12783395.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Liver Transpl. 2004 Mar;10(3):449-55 [15004776.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] N Engl J Med. 1995 May 11;332(19):1256-61 [7708069.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3 [9409568.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):788-94 [15760403.001]
  • (PMID = 19036146.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN24081794
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2630329
  •  go-up   go-down


78. Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, Cherqui D, Tran Van Nhieu J: Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol; 2008 Dec;15(12):3440-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy has also an effect on primary tumor in colon carcinoma.
  • BACKGROUND: This study characterizes the histological effect of chemotherapy (CT) on primary colonic tumors.
  • METHODS: Between 2000 and 2006, 38 patients with stage IV colon cancer underwent resection of the primary, after chemotherapy (CT group, n = 16) or without preoperative CT (control group, n = 22).
  • For all primary tumors, histological analysis included: fibrosis, acellular necrosis, acellular mucin pools, lymphoplasmacytic infiltration, and changes at tumor surface.
  • TRG in the primary was comparable to the TRG in the corresponding liver metastases for 7/9 patients who underwent both colonic and hepatic resection after CT.
  • Response to CT in the primary and the corresponding liver metastases are correlated.
  • These results support a policy of initial CT management for stage IV colon cancer and may warrant future studies of neoadjuvant CT in locally advanced colon carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / drug therapy. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850249.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol; 2005 Jul;174(1):93-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.
  • PURPOSE: Primary neuroendocrine tumors of the bladder are rare and they include small and large cell variants.
  • MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer at our institution, of whom 25 (1.2%) had neuroendocrine tumors of the bladder, including small cell carcinoma in 20 and large cell carcinoma in 5.
  • A total of 19 patients (76%) had lymph node involvement, of whom 2 had small liver metastases found intraoperatively, while only 4 (16%) had organ confined tumors and 2 (8%) had extravesical, node negative disease.
  • CONCLUSIONS: Neuroendocrine tumors of the bladder usually present with advanced pathological stage and portend a poor prognosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947585.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Poultsides G, Brown M, Orlando R 3rd: Hand-assisted laparoscopic management of liver tumors. Surg Endosc; 2007 Aug;21(8):1275-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted laparoscopic management of liver tumors.
  • BACKGROUND: Laparoscopy has clearly advanced the treatment of many diseases related to the liver and biliary tree.
  • The addition of hand assistance can further facilitate minimally invasive liver surgery by providing tactile feedback, atraumatic and versatile retraction, finger-fracture parenchyma dissection, and more precise placement of probes and staplers.
  • METHODS: Over a 7-year period, 28 patients with liver tumors underwent 31 hand-assisted laparoscopic operations at a tertiary care center.
  • The candidates for hand-assisted laparoscopic resection were patients with lesions involving two hepatic segments or fewer located at the inferior edge of the liver (segments 5 and 6), or confined to the left lateral segment (segments 2 and 3).
  • A total of 19 patients (68%) had metastatic disease, and 3 (11%) had primary liver cancer.
  • A group of 15 patients who had metastatic colorectal cancer treated with resection and/or ablation had a mean follow-up period of 24 months (range, 2-61 months) and a mean survival time of 36 months.
  • CONCLUSIONS: For selected patients, the hand-assisted technique can be applied safely and effectively to laparoscopic liver surgery and may identify the presence of previously undetectable intrahepatic or extrahepatic disease.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laparoendosc Surg. 1996 Mar;6 Suppl 1:S61-3 [8832930.001]
  • [Cites] Surg Endosc. 1995 Jun;9(6):733-5 [7482177.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):451-62 [15062655.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):407-11; discussion 412 [11926943.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1363 [12235510.001]
  • [Cites] Br J Surg. 1993 Dec;80(12 ):1571-4 [8298929.001]
  • [Cites] Surg Endosc. 1996 Jul;10(7):758-61 [8662435.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):93-100 [9208969.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Arch Surg. 1999 May;134(5):477-85; discussion 485-6 [10323419.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):34-43 [10631360.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):854-9 [10896382.001]
  • [Cites] Arch Surg. 1997 May;132(5):505-10; discussion 511 [9161393.001]
  • [Cites] Ann Surg. 2000 May;231(5):715-23 [10767793.001]
  • (PMID = 17479339.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Slupski MW, Szczylik C, Jasinski MK: Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol; 2007;5:36
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma.
  • BACKGROUND: Cholangiocellular cancers account for about 10-15% of primary liver cancers.
  • CASE PRESENTATION: The case described shows remission of a disseminated cholangiocellular carcinoma (focal changes in liver, metastases to lungs) after neoadjuvant chemotherapy.
  • After remission of lesions in lungs and reduction/regression of tumours in liver to one focal change, right lobe liver resection was performed.
  • The histopathological examination did not reveal any viable carcinoma cells, only necrotic tissues in place of the primary tumour as well as in local portal vein branches was seen.
  • CONCLUSION: Appropriate neoadjuvant chemotherapy may allow radical resection in a previously unresectable cholangiocellular cancer.
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Interferon-alpha / administration & dosage. Male. Neoadjuvant Therapy. Recombinant Proteins

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Sep;87(9):1182-7 [10971425.001]
  • [Cites] Braz J Med Biol Res. 2004 Nov;37(11):1689-705 [15517086.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1192-6 [12181241.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Ann Oncol. 2004 May;15(5):770-4 [15111345.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 May;3(2):279-83 [15138126.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1245-8 [6092556.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):537-44 [8268770.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2311-5 [8708722.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):41-7 [9683753.001]
  • [Cites] Oncology. 1999 Apr;56(3):177-80 [10202270.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):122-7 [10398898.001]
  • [Cites] Semin Liver Dis. 1999;19(3):271-85 [10518307.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3375-80 [11705850.001]
  • (PMID = 17376238.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 80168379AG / Doxorubicin; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; PIAF regimen
  • [Other-IDs] NLM/ PMC1839091
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


82. Newman E, Potmesil M, Ryan T, Marcus S, Hiotis S, Yee H, Norwood B, Wendell M, Muggia F, Hochster H: Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Semin Oncol; 2005 Dec;32(6 Suppl 9):S97-100
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
  • A phase II trial, using neoadjuvant chemotherapy and intraperitoneal (IP) consolidation, was conducted in patients with locally advanced, potentially resectable gastric cancer or cancer of the gastroesophageal junction, both staged as T3N0, T4N0, or any TN1 or TN2 disease.
  • Evidence of primary-tumor downstaging was documented in at least one half of the patients.
  • Sites of first recurrences were outside the abdominal cavity in seven patients, in the liver in two, and in the abdominal cavity in four patients.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Esophagectomy. Female. Floxuridine / administration & dosage. Floxuridine / adverse effects. Gastrectomy. Humans. Infusions, Parenteral. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399443.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


83. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT: A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer; 2010 Sep 28;103(7):954-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
  • METHODS: Patients with advanced HCC who were not candidates for local therapy were eligible and randomly assigned to receive weekly intramuscular injections of ADI-PEG 20 at doses of 160 or 320 IU m(-2).
  • The primary end point was disease-control rate (DCR).
  • CONCLUSIONS: ADI-PEG 20 is safe and efficacious in stabilising the progression of heavily pretreated advanced HCC in an Asian population, and deserves further exploration.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hydrolases / therapeutic use. Liver Neoplasms / drug therapy. Polyethylene Glycols / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arginine / blood. Asian Continental Ancestry Group. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retreatment

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2007 Dec;12(12):1425-32 [18165619.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):250-9 [18041064.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Int J Cancer. 2008 Oct 15;123(8):1950-5 [18661517.001]
  • [Cites] Curr Oncol Rep. 2008 May;10(3):199-205 [18765149.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] Autophagy. 2009 May;5(4):567-8 [19276647.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):e271; author reply e272 [19917866.001]
  • [Cites] Int J Cancer. 2010 Jun 15;126(12):2762-72 [20104527.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2220-6 [20351325.001]
  • [Cites] Gut. 2003 May;52 Suppl 3:iii1-8 [12692148.001]
  • [Cites] Am J Epidemiol. 2003 Apr 15;157(8):674-82 [12697571.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):723-8 [12866032.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1214-6 [14571701.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):826-33 [14770441.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1815-22 [15143074.001]
  • [Cites] Liver. 1986 Jun;6(3):133-7 [2427909.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):345-9 [2403840.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):244-9 [1568792.001]
  • [Cites] Jpn J Cancer Res. 1993 Nov;84(11):1195-200 [8276724.001]
  • [Cites] J Infect Dis. 1963 Jan-Feb;112:7-16 [14031982.001]
  • [Cites] Proc Soc Exp Biol Med. 1963 Feb;112:381-7 [14035371.001]
  • [Cites] Proc Soc Exp Biol Med. 1964 Dec;117:910-8 [14244988.001]
  • [Cites] Exp Cell Res. 1960 Jun;20:84-91 [13840125.001]
  • [Cites] J Gastroenterol. 2005 Mar;40(3):225-35 [15830281.001]
  • [Cites] Nat Rev Immunol. 2005 Aug;5(8):641-54 [16056256.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):30-5 [16356828.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Oct;21(10):1561-6 [16928217.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Immunobiology. 2007;212(9-10):795-812 [18086380.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Control Release. 2002 Apr 23;80(1-3):259-71 [11943403.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5443-50 [12359751.001]
  • [Cites] J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S109-14 [12394214.001]
  • [Cites] Biomed Pharmacother. 2002 Nov;56(9):439-45 [12481980.001]
  • [Cites] Rev Gastroenterol Disord. 2003 Winter;3(1):8-24 [12684589.001]
  • (PMID = 20808309.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 94ZLA3W45F / Arginine; EC 3.- / Hydrolases; EC 3.5.3.6 / ADI PEG20
  • [Other-IDs] NLM/ PMC2965867
  •  go-up   go-down


84. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC: Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep; 2008 Apr;19(4):1045-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
  • Cancer cells with a high glycolytic rate have an advantage in tumor growth.
  • HKII mRNA was overexpressed in 70 (35%) primary HCCs.
  • In conclusion, the aberrant expression of ALDOB and HKII is associated with advanced disease, ETR and poor prognosis, and ALDOB down-regulation in stage II HCC is a predictive marker of ETR and an unfavorable outcome.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Fructose-Bisphosphate Aldolase / genetics. Hexokinase / genetics. Liver Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Enzymologic. Genes, p53. Humans. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357395.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.1.1 / Hexokinase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


85. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK: Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg; 2010 Jun;210(6):934-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
  • BACKGROUND: An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection.
  • STUDY DESIGN: Data on 156 consecutive patients with synchronous resectable CLM and intact primary were reviewed.
  • Surgical strategies were defined as combined (combined resection of primary and liver), classic (primary before liver), and reverse (liver before primary) after preoperative chemotherapy.
  • On multivariate analysis, liver tumor size >3 cm (hazard ratio [HR] 2.72, 95% CI 1.52 to 4.88) and cumulative postoperative morbidity (HR 1.8, 95% CI 1.03 to 3.19) were independently associated with overall survival after surgery.
  • The reverse strategy can be considered as an alternative option in patients with advanced CLM and an asymptomatic primary.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Surgery / methods. Combined Modality Therapy. Female. Hepatectomy / methods. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Statistics, Nonparametric. Survival Rate. Treatment Outcome


86. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL: Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer; 2007 Sep 3;97(5):582-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
  • To assess the efficacy of the combination of long-acting release (LAR) octreotide and tamoxifen (TMX) for the treatment of advanced hepatocellular carcinoma (HCC).
  • A total of 109 patients with advanced HCC were randomised to receive octreotide LAR combined with TMX (n=56) (experimental treatment group) or TMX alone (n=53; control group).
  • Primary end point was patient survival; secondary end points were the impact of therapy on tumour response, quality of life and variceal bleeding episodes.
  • The combination of octreotide LAR and TMX does not influence survival, tumour progression or quality of life in patients with advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diarrhea / chemically induced. Female. Humans. Male. Middle Aged. Multivariate Analysis. Nausea / chemically induced. Neoplasm Staging. Octreotide / administration & dosage. Octreotide / adverse effects. Patient Compliance / statistics & numerical data. Prognosis. Quality of Life. Survival Analysis. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998;77(1):115-22 [9459155.001]
  • [Cites] Digestion. 1996;57 Suppl 1:29-33 [8813463.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12(2):111-26 [9692685.001]
  • [Cites] Lancet. 1998 Jul 4;352(9121):17-20 [9800740.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1284-92 [10189133.001]
  • [Cites] Gut. 1999 Nov;45(5):766-74 [10517918.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1361-9 [15565568.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):694-701 [15763644.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1408-14 [15744746.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4338-46 [15994145.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1435-48 [16530734.001]
  • [Cites] Hepatology. 2007 Jan;45(1):9-15 [17187405.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):218-22 [10638587.001]
  • [Cites] Hepatology. 2000 Jan;31(1):54-8 [10613728.001]
  • [Cites] Am J Gastroenterol. 2007 Jul;102(7):1397-405 [17488248.001]
  • [Cites] Int J Oncol. 2000 Jun;16(6):1197-201 [10811995.001]
  • [Cites] J Hepatol. 2000 Nov;33(5):846-52 [11097497.001]
  • [Cites] Bull Cancer. 2000 Dec;87(12):881-6 [11174117.001]
  • [Cites] Mol Pathol. 2001 Jun;54(3):138-44 [11376124.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Z Gastroenterol. 2002 Jun;40(6):395-400 [12055662.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):903-7 [12066229.001]
  • [Cites] Hepatology. 2002 Sep;36(3):687-91 [12198662.001]
  • [Cites] Hepatogastroenterology. 2002 Sep-Oct;49(47):1245-50 [12239914.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):327-34 [12811549.001]
  • [Cites] Acta Gastroenterol Belg. 2004 Jan-Mar;67(1):14-25 [15149081.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1474-84 [15196530.001]
  • [Cites] Gut. 2004 Aug;53(8):1180-9 [15247189.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):112-8 [15246216.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Endocrinology. 1992 Nov;131(5):2479-81 [1385103.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Aug 30;203(1):253-9 [8074663.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6334-7 [7987824.001]
  • [Cites] Hepatology. 1995 Jun;21(6):1535-42 [7768497.001]
  • [Cites] Gut. 1998 Mar;42(3):442-7 [9577356.001]
  • (PMID = 17687341.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 094ZI81Y45 / Tamoxifen; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2360361
  •  go-up   go-down


87. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol; 2010 May;11(5):421-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
  • BACKGROUND: Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer.
  • The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer.
  • Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function.
  • The primary endpoint was the number of patients with detectable DTCs at 3 months.
  • [MeSH-minor] Adult. Aged. Bone Marrow / pathology. Female. Humans. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Dent Res. 2007 Nov;86(11):1022-33 [17959891.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):820-8 [17159195.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1001-10 [18205185.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2644-52 [18427147.001]
  • [Cites] Oncologist. 2008 May;13(5):503-14 [18515735.001]
  • [Cites] Cancer Treat Rev. 2008;34 Suppl 1:S19-24 [18486348.001]
  • [Cites] J Bone Miner Res. 2008 Jun;23(6):826-36 [18558816.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):193-201 [18459173.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78 [18695136.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):840-9 [18718815.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4739-45 [18711172.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jun;6(6):339-51 [19399023.001]
  • [Cites] Br J Cancer. 2010 Mar 30;102(7):1099-105 [20234364.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):80-6 [10623696.001]
  • [Cites] Blood. 2000 Jul 15;96(2):384-92 [10887096.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1126-34 [11308265.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):653-61 [11870242.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):834-9 [12548583.001]
  • [Cites] Am J Med. 2003 Jun 1;114(8):653-9 [12798453.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2893-7 [12912933.001]
  • [Cites] Blood. 1994 Feb 1;83(3):623-5 [7905297.001]
  • [Cites] Blood. 1994 Feb 1;83(3):636-40 [7507729.001]
  • [Cites] Dtsch Med Wochenschr. 2008 Feb;133(7):285-9 [18253918.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] Acta Oncol. 2004;43(7):650-6 [15545185.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):619-29 [15545664.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3314-21 [15738536.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3209-14 [15769994.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]
  • [Cites] Pathol Oncol Res. 2005;11(3):186-7 [16299941.001]
  • [Cites] Future Oncol. 2005 Apr;1(2):149-59 [16555985.001]
  • [Cites] Tumour Biol. 2006;27(2):92-103 [16582586.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R13 [16542503.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):885-92 [16874814.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6309s-6314s [17062720.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):829-36 [17159193.001]
  • [CommentIn] Lancet Oncol. 2010 May;11(5):402-3 [20434707.001]
  • (PMID = 20362507.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00242203
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730; United States / NCI NIH HHS / CA / R01 CA097250
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ NIHMS405760; NLM/ PMC3792651
  •  go-up   go-down


88. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA: A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol; 2010 Oct;21(10):1999-2004
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
  • This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction.
  • PATIENTS AND METHODS: Previously untreated patients with locally advanced or metastatic disease and a performance status (PS) of 0-1 were eligible for this study.
  • The primary end point of the study was progression-free survival (PFS).

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lancet Oncol. 2009 Jun;10(6):559-68 [19482548.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):171-4 [1705485.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Pathol Int. 1998 Jul;48(7):499-506 [9701011.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):933-6 [9714067.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):264-70 [10437615.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Ann Oncol. 2007 Dec;18(12):2006-8 [17951596.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):104-8 [17897959.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):542-6 [18212754.001]
  • [Cites] Anticancer Drugs. 2008 Jun;19(5):535-9 [18418220.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5326-34 [18854571.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):347-53 [19066894.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • (PMID = 20332133.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2980934
  •  go-up   go-down


89. Iizuka M, Sengoku N, Nakakuma T, Yoshimura N, Hayashi K, Enomoto T, Kuranami M, Watanabe M: [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2228-30
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
  • We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL.
  • Subsequently, radiographic imaging tests revealed that the tumor had metastasized to the liver and lungs, as well as the skull.
  • Accordingly, a primary systemic chemotherapy (4 series of AC/T) was started and followed by local radiation therapy (60 Gys) immediately after completing the chemotherapy.
  • The metastasizing lesions in the liver, lungs, and skull had markedly reduced in the size and number, and the skin ulceration had healed up by these treatments.
  • She has been quite well without any adverse effects by S-1 and TAM, and the primary as well as metastasizing lesions remain stable with normalized tumor marker levels (NC) for nearly 3 years.
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Drug Combinations. Female. Humans. Mitoxantrone / therapeutic use. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed. Topotecan / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106579.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 04079A1RDZ / Cytarabine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; AC protocol; TAM protocol
  •  go-up   go-down


90. Artigas V, Marín-Hargreaves G, Marcuello E, Pey A, González JA, Rodríguez M, Moral A, Monill JM, Sancho J, Pericay C, Trias M: [Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital]. Cir Esp; 2007 Jun;81(6):339-44
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital].
  • INTRODUCTION: Surgical resection is the only available treatment that improves survival in patients with liver metastases from colorectal cancer, particularly when carried out by a multidisciplinary team.
  • MATERIAL AND METHOD: We retrospectively analyzed a consecutive series of 116 patients who underwent 138 liver resections (65.4% minor and 35.5% major) for hepatic metastases from colorectal cancer between 1998 and 2004.
  • In 67.3% of the patients, the primary tumor was at an advanced stage (III-IV).
  • Survival rates varied according to whether the patients had < 4 or > or = 4 colorectal liver metastases (50 and 43 months respectively), tumor size (more or less than 5 cm) (60 and 50.6 months respectively) and whether the site was monolobar or bilobar (60 and 43.11 months respectively).
  • In 16 patients, recurrence of liver metastases led to 22 rehepatectomies.
  • CONCLUSIONS: These results confirm that multidisciplinary decisions and interventions by specialist liver surgeons, as in our hospital, reduce postoperative morbidity and mortality and increase survival in patients requiring surgical removal of liver metastases from colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / secondary. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hospitalization. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553407.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


91. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS: The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol; 2008 Feb;108(2):287-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
  • OBJECTIVE: To analyze the impact of bulky upper abdominal disease (UAD) cephalad to the greater omentum on surgical outcomes for patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma.
  • METHODS: All patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma who underwent primary cytoreductive surgery at our institution from 1989 to 2005 were eligible for the study.
  • UAD cephalad to the greater omentum was defined as cancerous lesions involving the diaphragm, liver, porta hepatis, spleen, pancreas, stomach, and lesser sac.
  • These findings emphasize the importance of comprehensive training, preparation, and referral when appropriate to centers that specialize in the surgical management of patients with advanced ovarian, tubal, and peritoneal carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging


92. Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C: Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer; 2010 Sep 07;103(6):837-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
  • METHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks.
  • The primary aim of the study was progression-free survival (PFS).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy. Oligopeptides / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2000 Nov;18(11):1185-90 [11062439.001]
  • [Cites] Clin Cancer Res. 2010 Feb 15;16(4):1315-23 [20145168.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):475-82 [12189241.001]
  • [Cites] FASEB J. 2004 Mar;18(3):554-6 [14734634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 [1103152.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:104-12 [15650236.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6657-63 [16170173.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):175-82 [16397040.001]
  • [Cites] Cancer Immun. 2006;6:6 [16551058.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4588-93 [17360568.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):581-9 [17583545.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):845-53 [17599769.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1059-67 [17623837.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2992-8 [18565886.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):19-23 [19018262.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):219-24 [19568235.001]
  • [Cites] Eur J Cancer. 2010 Jan;46(1):198-206 [19900802.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):867-74 [11830545.001]
  • (PMID = 20717115.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / NGR peptide; 0 / Oligopeptides; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2966632
  •  go-up   go-down


93. van der Pool AE, Lalmahomed ZS, Ozbay Y, de Wilt JH, Eggermont AM, Jzermans JN, Verhoef C: 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis; 2010 Oct;12(10 Online):e229-35
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome.
  • AIM: Approximately 25% of the patients with colorectal cancer already have liver metastases at diagnosis and another 30% will develop them subsequently.
  • The features and prognosis of patients with synchronous and metachronus colorectal liver metastases, treated with primary resection first followed by partial liver resection were analysed.
  • METHOD: Curative staged resection of liver metastases was performed in 272 consecutive patients.
  • Demographics, characteristics of the primary tumour and metastatic tumours, surgery-related data and outcome were analysed.
  • More patients in the synchronous group had an advanced primary tumour (T3/T4 and/or node positivity), more than three liver metastases and bilobar distribution.
  • CONCLUSION: Although patients with synchronous colorectal liver metastases may have poorer biological features, there was no difference in 5-year disease-free and overall survival compared with patients with metachronous metastases.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Male. Middle Aged. Neoadjuvant Therapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19912286.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Zhou L, Yang YP, Feng YY, Lu YY, Wang CP, Wang XZ, An LJ, Zhang X, Wang FS: Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. Ai Zheng; 2009 Jan;28(1):45-8
Hazardous Substances Data Bank. HELIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study.
  • BACKGROUND AND OBJECTIVE: Recent years, great progression has been made in treating primary hepatocellular carcinoma (HCC) with argon-helium cryosurgical ablation.
  • This study was to evaluate its efficacy on unresectable primary HCC.
  • METHODS: A total of 124 primary HCC patients were divided into early stage, middle stage and advanced stage groups according to BCLC staging classification.
  • The median survival time was 31.25 months in early stage group, 17.41 months in middle stage group and 6.82 months in advanced stage group.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cryosurgery / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Argon. Female. Helium. Humans. Liver / physiopathology. Male. Middle Aged. Pilot Projects. Postoperative Complications / epidemiology. Survival Rate. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448416.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 206GF3GB41 / Helium; 67XQY1V3KH / Argon
  •  go-up   go-down


95. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • AIM: To assess subcellular localization of KL-6 mucin and its clinicopathological significance in colorectal carcinoma as well as metastatic lymph node and liver tissues.
  • METHODS: Colorectal carcinoma tissues as well as metastatic lymph node and liver tissues were collected from 82 patients who underwent colorectomy or hepatectomy.
  • Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion (P = 0.0003), lymphatic invasion (P<0.0001), lymph node metastasis (P<0.0001), liver metastasis (P = 0.058), and advanced histological stage (P<0.0001).
  • Positive staining was observed in all metastatic lesions tested as well as in the primary colorectal carcinoma tissues.
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Mucin-1. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


96. Stapley S, Peters TJ, Sharp D, Hamilton W: The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records. Br J Cancer; 2006 Nov 20;95(10):1321-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records.
  • The association between the staging of colorectal cancer and mortality is well known.
  • We performed a cohort study of 349 patients with primary colorectal cancer in whom all their prediagnostic symptoms and investigation results were known.
  • Survival data for 3-8 years after diagnosis were taken from the cancer registry.
  • Rectal bleeding as an initial symptom was associated with less advanced staging (odds ratio from one Duke's stage to the next 0.50, 95% confidence interval 0.31, 0.79; P=0.003) and with reduced mortality (Cox's proportional hazard ratio (HR) 0.56 (0.41, 0.79); P=0.001.
  • Mild anaemia, with a haemoglobin of 10.0-12.9 g dl(-1), was associated with more advanced staging (odds ratio 2.2 (1.2, 4.3); P=0.021) and worse mortality (HR 1.5 (0.98, 2.3): P=0.064).
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Constipation / etiology. Diarrhea / etiology. Female. Gastrointestinal Hemorrhage / etiology. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Occult Blood. Predictive Value of Tests. Weight Loss

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1991 Feb;61(2):137-40 [2001199.001]
  • [Cites] Eur J Surg Oncol. 1989 Oct;15(5):441-5 [2551743.001]
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):173-8 [10218461.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3039-45 [10520866.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):169-71 [15720357.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):399-405 [16106247.001]
  • [Cites] Fam Pract. 2006 Feb;23(1):15-9 [16286462.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):423-9 [16684087.001]
  • [Cites] Colorectal Dis. 2006 Jul;8(6):518-21 [16784474.001]
  • [Cites] BMJ. 2006 Jul 8;333(7558):69-70 [16790459.001]
  • [Cites] Colorectal Dis. 2006 Oct;8(8):688-95 [16970580.001]
  • [Cites] BMJ. 2001 Jun 30;322(7302):1555-6 [11431280.001]
  • [Cites] Dig Liver Dis. 2000 May;32(4):312-7 [11515629.001]
  • [Cites] Postgrad Med J. 2002 Sep;78(923):533-7 [12357013.001]
  • [Cites] Ann R Coll Surg Engl. 2002 Nov;84(6):381-5 [12484575.001]
  • [Cites] Scand J Gastroenterol. 2004 Mar;39(3):252-8 [15074395.001]
  • [Cites] World J Surg. 2004 Jul;28(7):716-20 [15383871.001]
  • [Cites] Eur J Surg Oncol. 1986 Jun;12(2):127-30 [3709816.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1461-7 [9337690.001]
  • (PMID = 17060933.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360591
  •  go-up   go-down


97. Sloane D, Chen H, Howell C: Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc; 2006 Dec;98(12):1934-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival.
  • OBJECTIVES: The incidence and mortality rates from primary hepatocellular carcinoma (HCC) are higher in black Americans compared to whites.
  • CONCLUSIONS: Black HCC patients have more advanced tumor stage at diagnosis and lower rates of both surgical intervention and survival.

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2060-3 [14499788.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):355-60 [16527700.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):601-9 [15280639.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):182-7 [9652250.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):413-8 [16365180.001]
  • [Cites] Liver Transpl. 2004 Jul;10(7):834-41 [15237365.001]
  • (PMID = 17225837.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 1 K24 DK072036-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569668
  •  go-up   go-down


98. Jiao LR, Szyszko T, Al-Nahhas A, Tait P, Canelo R, Stamp G, Wasan H, Lowdell C, Philips R, Thillainayagam A, Bansi D, Rubello D, Limongelli P, Woo K, Habib NA: Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol; 2007 Jun;33(5):597-602
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours.
  • MATERIAL AND METHODS: From June 2004, patients whose liver tumours were no longer amenable for any conventional treatment with either chemotherapy or surgery were considered for yttrium-90 microspheres treatment after discussion at our multidisciplinary meeting.
  • RESULT: Twenty-one patients (F=11, M=10; age range 40-75 years, mean=58 years) received yttrium-90 microspheres consisting of liver metastases from colorectal primary (n=10) and non-colorectal primaries (n=8), and primary liver tumours (n=3).
  • Injection of microspheres had no immediate effect on either clinical haematology or liver function tests.
  • For patients with colorectal liver metastases, there was no significant reduction in CEA level (127+/-115 vs 75+/-72 micro/l, p=0.39).
  • CONCLUSION: SIRT should be considered for patients with advanced liver cancer.
  • It has a significant effect on liver disease in the absence of extrahepatic disease.
  • [MeSH-major] Liver Neoplasms / radiotherapy. Microspheres. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms. Female. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433608.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


99. Alberts SR, Roh MS, Mahoney MR, O'Connell MJ, Nagorney DM, Wagman L, Smyrk TC, Weiland TL, Lai LL, Schwarz RE, Molina R, Dentchev T, Bolton JS: Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol; 2010 Feb 10;28(5):853-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.
  • Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer.
  • The primary end point was 2-year survival.
  • PATIENTS AND METHODS Patients with liver-only metastases from colorectal cancer amenable to resection or cryoablation were eligible.
  • With a median follow-up of 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Catheter Ablation. Colorectal Neoplasms / pathology. Cryosurgery. Hepatectomy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Capecitabine. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dexamethasone / administration & dosage. Drug Administration Schedule. Feasibility Studies. Female. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Hepatic Artery. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Proportional Hazards Models. Risk Assessment. Time Factors. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4591-6 [12454117.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):248-53 [12657235.001]
  • [Cites] Colorectal Dis. 2003 Jan;5(1):2-23 [12780921.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):659-71 [15062667.001]
  • [Cites] Clin Colorectal Cancer. 2012 Mar;11(1):31-7 [21729678.001]
  • [Cites] Cancer. 1993 Jun 15;71(12 Suppl):4252-66 [8508388.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):514-23 [10528899.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):734-5 [15716576.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7125-34 [16192596.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] Arch Surg. 1976 Apr;111(4):330-4 [1259571.001]
  • (PMID = 20048179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00026234
  • [Grant] United States / NCI NIH HHS / CA / U10 CA052352; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / U10 CA035448; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / CA25224-18; United States / NCI NIH HHS / CA / U10 CA035272; United States / NCI NIH HHS / CA / U10 CA035101; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035103
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 039LU44I5M / Floxuridine; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7S5I7G3JQL / Dexamethasone; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2834397
  •  go-up   go-down


100. Tinoco RC, Tinoco AC, El-Kadre LJ, Sueth DM, Conde LM: Laparoscopic gastrectomy for gastric cancer. Surg Laparosc Endosc Percutan Tech; 2009 Oct;19(5):384-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic gastrectomy for gastric cancer.
  • BACKGROUND: Surgery in gastric cancer (GC) aims to achieve resection of the primary tumor and its lymphatic drain, with a minimal adverse effect on morbidity and mortality, and the best possible quality of life.
  • After peritoneal cavity inspection, laparoscopic ultrasound was used to determine the presence of deep liver metastasis.
  • Laparoscopic gastrectomy is a safe and effective option for the treatment of GC, avoiding nontherapeutic laparotomy in patients with advanced disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Roux-en-Y. Brazil. Duodenum / surgery. Female. Gastroenterostomy. Humans. Lymph Node Excision / instrumentation. Lymph Node Excision / methods. Male. Middle Aged. Omentum / surgery. Reoperation / statistics & numerical data. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851265.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement